{
    "url": "https://www.sec.gov/Archives/edgar/data/1053369/000149315224006661/form10-q.htm",
    "report_type": "10-Q",
    "context": [
        {
            "id": 0,
            "context": "ITEM 1. FINANCIAL STATEMENTS\n\n| December 31, 2023 | March 31, 2023 |\n| ASSETS |\n| Current assets: |\n| Cash | $ | 5,816,211 | $ | 7,832,247 |\n| Accounts receivable, net of allowance for expected credit losses of $ 194,600 and $ 0 as of December 31, 2023 and March 31, 2023, respectively | 16,009,614 | 3,094,549 |\n| Inventory | 14,325,041 | 9,550,716 |\n| Prepaid expenses and other current assets | 1,005,636 | 1,032,785 |\n| Total current assets | 37,156,502 | 21,510,297 |\n| Property and equipment, net of accumulated depreciation of $ 15,578,471 and $ 14,586,335 respectively | 10,095,029 | 10,426,158 |\n| Intangible assets, net of accumulated amortization of $- 0 - | 6,341,228 | 6,341,228 |\n| Finance lease - right-of-use asset | 408,428 | \u2014 |\n| Operating lease - right-of-use asset | 26,231 | 13,062 |\n| Deferred income tax asset | 20,233,603 | 2,171,821 |\n| Other assets: |\n| Restricted cash - debt service for NJEDA bonds | 427,999 | 412,434 |\n| Security deposits | 7,259 | 21,018 |\n| Total other assets | 435,258 | 433,452 |\n| Total assets | $ | 74,696,279 | $ | 40,896,018 |\n| LIABILITIES AND SHAREHOLDERS\u2019 EQUITY |\n| Current liabilities: |\n| Accounts payable | $ | 2,890,717 | $ | 2,446,810 |\n| Accrued expenses | 11,884,645 | 5,047,726 |\n| Deferred revenue, current portion | 13,333 | 13,333 |\n| Bonds payable, current portion, net of bond issuance costs | 115,822 | 110,822 |\n| Loans payable, current portion | 190,607 | 200,032 |\n| Related party loans payable (Note 7) | 4,000,000 | \u2014 |\n| Lease obligation - finance lease, current portion | 37,444 | \u2014 |\n| Lease obligation - operating lease, current portion | 26,231 | 14,914 |\n| Total current liabilities | 19,158,799 | 7,833,637 |\n| Long-term liabilities: |\n| Deferred revenue, net of current portion | 8,889 | 18,890 |\n| Bonds payable, net of current portion and bond issuance costs | 909,654 | 1,029,018 |\n| Loans payable, net of current portion and loan costs | 2,407,077 | 2,532,502 |\n| Lease obligation - finance lease, net of current portion | 200,939 | \u2014 |\n| Derivative financial instruments - warrants | 5,597,200 | 521,711 |\n| Total long-term liabilities | 9,123,759 | 4,102,121 |\n| Total liabilities | 28,282,558 | 11,935,758 |\n| Shareholders\u2019 equity: |\n| Common Stock; par value $ 0.001 ; 1,445,000,000 shares authorized; 1,017,881,199 and 1,014,015,081 shares issued as of December 31, 2023 and March 31, 2023, respectively; 1,017,781,199 and 1,013,915,081 shares outstanding as of December 31, 2023 and March 31, 2023, respectively | 1,017,885 | 1,014,019 |\n| Additional paid-in capital | 165,417,811 | 164,750,980 |\n| Treasury stock; 100,000 shares as of December 31, 2023 and March 31, 2023, respectively, at cost | ( 306,841 | ) | ( 306,841 | ) |\n| Accumulated deficit | ( 119,715,134 | ) | ( 136,497,898 | ) |\n| Total shareholders\u2019 equity | 46,413,721 | 28,960,260 |\n| Total liabilities and shareholders\u2019 equity | $ | 74,696,279 | $ | 40,896,018 |",
            "type": "table"
        },
        {
            "id": 1,
            "context": "The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n(UNAUDITED)\n\n| For the Three Months Ended December 31, | For the Nine Months Ended December 31, |\n| 2023 | 2022 | 2023 | 2022 |\n| Revenue: |\n| Manufacturing fees | $ | 14,791,110 | $ | 7,798,159 | $ | 36,208,217 | $ | 21,312,663 |\n| Licensing fees | 747,690 | 1,451,907 | 2,467,844 | 4,200,888 |\n| Total revenue | 15,538,800 | 9,250,066 | 38,676,061 | 25,513,551 |\n| Cost of manufacturing | 8,497,727 | 4,330,841 | 20,437,354 | 12,360,935 |\n| Gross profit | 7,041,073 | 4,919,225 | 18,238,707 | 13,152,616 |\n| Operating expenses: |\n| Research and development | 1,403,790 | 1,443,361 | 5,165,684 | 3,775,107 |\n| General and administrative | 1,711,275 | 1,186,049 | 4,906,187 | 4,356,752 |\n| Non-cash compensation through issuance of stock options | 49,815 | 13,030 | 107,592 | 24,325 |\n| Depreciation and amortization | 343,537 | 317,685 | 999,059 | 933,531 |\n| Total operating expenses | 3,508,417 | 2,960,125 | 11,178,522 | 9,089,715 |\n| Income from operations | 3,532,656 | 1,959,100 | 7,060,185 | 4,062,901 |\n| Other income (expense): |\n| Change in fair value of derivative financial instruments - warrants | ( 2,417,772 | ) | 372,894 | ( 5,075,489 | ) | 561,070 |\n| Change in fair value of stock-based liabilities | ( 2,854,556 | ) | \u2014 | ( 4,921,376 | ) | \u2014 |\n| Interest expense and amortization of debt issuance costs | ( 121,628 | ) | ( 322,681 | ) | ( 371,478 | ) | ( 782,221 | ) |\n| Gain from settlement agreements | 1,761,792 | \u2014 | 1,761,792 | \u2014 |\n| Gain on sale of ANDA | \u2014 | 1,000,000 | \u2014 | 1,000,000 |\n| Interest income | 5,249 | 15 | 16,085 | 187 |\n| Other (expense) income, net | ( 3,626,915 | ) | 1,050,228 | ( 8,590,466 | ) | 779,036 |\n| (Loss) income before income taxes | ( 94,259 | ) | 3,009,328 | ( 1,530,281 | ) | 4,841,937 |\n| Income tax benefit (expense) | 800,613 | ( 39,250 | ) | 18,313,045 | ( 50,837 | ) |\n| Net income attributable to common shareholders | $ | 706,354 | $ | 2,970,078 | $ | 16,782,764 | $ | 4,791,100 |\n| Basic net income per share attributable to common shareholders | $ | 0.00 | $ | 0.00 | $ | 0.02 | $ | 0.00 |\n| Diluted net income per share attributable to common shareholders | $ | 0.00 | $ | 0.00 | $ | 0.02 | $ | 0.01 |\n| Basic weighted average Common Stock outstanding | 1,014,768,071 | 1,013,915,081 | 1,014,265,162 | 1,012,480,115 |\n| Diluted weighted average Common Stock outstanding | 1,024,448,445 | 1,013,915,081 | 1,019,511,813 | 1,012,480,115 |",
            "type": "table"
        },
        {
            "id": 2,
            "context": "The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY\n(UNAUDITED)\n\n| Series J Preferred Stock | Common Stock | Additional Paid-In | Treasury Stock | Accumulated | Total Shareholders\u2019 |\n| Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Equity |\n| Balance as of April 1, 2023 | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,750,980 | 100,000 | $ | ( 306,841 | ) | $ | ( 136,497,898 | ) | $ | 28,960,260 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 1,141,809 | 1,141,809 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 15,000 | \u2014 | \u2014 | \u2014 | 15,000 |\n| Balance at June 30, 2023 | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,765,980 | 100,000 | $ | ( 306,841 | ) | $ | ( 135,356,089 | ) | $ | 30,117,069 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 14,934,601 | 14,934,601 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 42,777 | \u2014 | \u2014 | \u2014 | 42,777 |\n| Balance at September 30, 2023 | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,808,757 | 100,000 | $ | ( 306,841 | ) | $ | ( 120,421,488 | ) | $ | 45,094,447 |\n| Shares issued in satisfaction of accrued director salaries | \u2014 | \u2014 | 1,642,971 | 1,643 | 250,224 | \u2014 | \u2014 | \u2014 | 251,867 |\n| Shares issued in satisfaction of accrued consultant fees | \u2014 | \u2014 | 2,223,147 | 2,223 | 309,015 | \u2014 | \u2014 | \u2014 | 311,238 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 706,354 | 706,354 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 49,815 | \u2014 | \u2014 | \u2014 | 49,815 |\n| Balance at December 31, 2023 | \u2014 | $ | \u2014 | 1,017,881,199 | $ | 1,017,885 | $ | 165,417,811 | 100,000 | $ | ( 306,841 | ) | $ | ( 119,715,134 | ) | $ | 46,413,721 |",
            "type": "table"
        },
        {
            "id": 3,
            "context": "The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY\n(UNAUDITED)\n\n| Series J Preferred Stock | Common Stock | Additional Paid-In | Treasury Stock | Accumulated | Total Shareholders\u2019 |\n| Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Equity |\n| Balance as of April 1, 2022 | \u2014 | \u2014 | 1,011,381,988 | $ | 1,011,385 | $ | 164,577,227 | 100,000 | $ | ( 306,841 | ) | $ | ( 140,059,744 | ) | $ | 25,222,027 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 305,883 | 305,883 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 5,322 | \u2014 | \u2014 | \u2014 | 5,322 |\n| Balance at June 30, 2022 | \u2014 | $ | \u2014 | 1,011,381,988 | $ | 1,011,385 | $ | 164,582,549 | 100,000 | $ | ( 306,841 | ) | $ | ( 139,753,861 | ) | $ | 25,533,232 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 1,515,139 | 1,515,139 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 5,974 | \u2014 | \u2014 | \u2014 | 5,974 |\n| Shares issued in payment of director salaries | \u2014 | \u2014 | 1,378,608 | 1,379 | 58,621 | \u2014 | \u2014 | \u2014 | 60,000 |\n| Shares issued in payment of consultant fees | \u2014 | \u2014 | 1,254,485 | 1,255 | 75,807 | \u2014 | \u2014 | \u2014 | 77,062 |\n| Balance at September 30, 2022 | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,722,951 | 100,000 | $ | ( 306,841 | ) | $ | ( 138,238,722 | ) | $ | 27,191,407 |\n| Balance | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,722,951 | 100,000 | $ | ( 306,841 | ) | $ | ( 138,238,722 | ) | $ | 27,191,407 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 2,970,078 | 2,970,078 |\n| Net income (Loss) | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 2,970,078 | 2,970,078 |\n| Non-cash compensation through the issuance of employee stock options | \u2014 | \u2014 | \u2014 | \u2014 | 13,029 | \u2014 | \u2014 | \u2014 | 13,029 |\n| Balance at December 31, 2022 | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,735,980 | 100,000 | $ | ( 306,841 | ) | $ | ( 135,268,644 | ) | $ | 30,174,514 |\n| Balance | \u2014 | $ | \u2014 | 1,014,015,081 | $ | 1,014,019 | $ | 164,735,980 | 100,000 | $ | ( 306,841 | ) | $ | ( 135,268,644 | ) | $ | 30,174,514 |",
            "type": "table"
        },
        {
            "id": 4,
            "context": "The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(UNAUDITED)\n\n| For the Nine Months Ended December 31, |\n| 2023 | 2022 |\n| CASH FLOWS FROM OPERATING ACTIVITIES: |\n| Net income | $ | 16,782,764 | $ | 4,791,100 |\n| Adjustments to reconcile net income to net cash (used in) provided by operating activities: |\n| Depreciation and amortization | 992,136 | 933,531 |\n| Bad debt expense | 194,600 | \u2014 |\n| Amortization of operating leases - right-of-use assets | 18,153 | 61,621 |\n| Non-cash compensation accrued | 563,105 | 430,778 |\n| Change in fair value of derivative financial instruments - warrants | 5,075,489 | ( 561,070 | ) |\n| Change in fair value of stock-based liabilities | 4,921,376 | \u2014 |\n| Gain on settlement of Common Stock to consultant | ( 1,761,792 | ) | \u2014 |\n| Non-cash compensation through the issuance of employee stock options | 107,592 | 24,325 |\n| Non-cash rent expense and lease accretion | \u2014 | 602 |\n| Deferred revenue | ( 10,001 | ) | ( 10,003 | ) |\n| Change in operating assets and liabilities: |\n| Accounts receivable | ( 13,109,665 | ) | ( 2,487,930 | ) |\n| Inventory | ( 4,774,325 | ) | ( 1,860,688 | ) |\n| Prepaid expenses and other current assets | 40,908 | ( 581,113 | ) |\n| Deferred income tax asset | ( 18,061,782 | ) | \u2014 |\n| Accounts payable, accrued expenses and other current liabilities | 3,702,825 | ( 309,950 | ) |\n| Interest expense of finance lease liability | ( 2,915 | ) | \u2014 |\n| Lease obligations - operating leases | ( 20,005 | ) | ( 61,182 | ) |\n| Net cash (used in) provided by operating activities | ( 5,341,537 | ) | 370,021 |\n| CASH FLOWS FROM INVESTING ACTIVITIES: |\n| Purchase of property and equipment | ( 406,007 | ) | ( 5,200,407 | ) |\n| Net cash used in investing activities | ( 406,007 | ) | ( 5,200,407 | ) |\n| CASH FLOWS FROM FINANCING ACTIVITIES: |\n| Payment of bond principal | ( 125,000 | ) | ( 115,000 | ) |\n| Proceeds from related party loans payable | 4,000,000 | \u2014 |\n| Proceeds from loans payable | \u2014 | 14,550,001 |\n| Amortization of finance leases - right-of-use assets | 6,923 | \u2014 |\n| Loan payments | ( 134,850 | ) | ( 230,770 | ) |\n| Net cash provided by financing activities | 3,747,073 | 14,204,231 |\n| Net change in cash and restricted cash | ( 2,000,471 | ) | 9,373,845 |\n| Cash and restricted cash, beginning of period | 8,244,681 | 8,940,396 |\n| Cash and restricted cash, end of period | $ | 6,244,210 | $ | 18,314,241 |\n| Supplemental disclosure of cash and non-cash transactions: |\n| Cash paid for interest | $ | 119,412 | $ | 782,221 |\n| Cash paid for income taxes | $ | 292,000 | $ | 127,522 |\n| Stock issued in satisfaction of accrued directors salaries and consultant fees | $ | 563,105 | $ | 137,067 |\n| Recognition of right of use asset and lease liabilities entered into | $ | 272,620 | $ | \u2014 |\n| Reconciliation of cash and restricted cash |\n| Cash | $ | 5,816,211 | $ | 17,909,077 |\n| Restricted cash - debt service for NJEDA bonds | 427,999 | 405,164 |\n| Total cash and restricted cash shown in statement of cash flows | $ | 6,244,210 | $ | 18,314,241 |",
            "type": "table"
        },
        {
            "id": 5,
            "context": "The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES\nOverview Elite Pharmaceuticals, Inc. (the \u201cCompany\u201d or \u201cElite\u201d) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary Elite Laboratories, Inc. (\u201cElite Labs\u201d) was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing, licensing, manufacturing, and sales of generic, oral dose pharmaceuticals. The Company is equipped to manufacture controlled-release products on a contract basis for third parties and itself, if and when the product candidates are approved. These products include drugs that cover therapeutic areas for allergy, bariatric, attention deficit and infection. Research and development activities are performed with an objective of developing product candidates that will secure marketing approvals from the United States Food and Drug Administration (\u201cFDA\u201d), and thereafter, commercially exploiting such products.",
            "type": "paragraph"
        },
        {
            "id": 6,
            "context": "Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (\u201cGAAP\u201d) and pursuant to the rules and regulations of the SEC. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Elite Labs. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company\u2019s Form 10-K as filed with the SEC on June 29, 2023. The interim results for the nine months ended December 31, 2023 are not necessarily indicative of the results to be expected for the fiscal year ending March 31, 2024 or for any future periods.",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "Segment Information Financial Accounting Standards Board (\u201cFASB\u201d) Accounting Standards Codification 280 (\u201cASC 280\u201d), Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance.",
            "type": "paragraph"
        },
        {
            "id": 8,
            "context": "The Company\u2019s chief operating decision maker is the Chief Executive Officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with GAAP when making decisions about allocating resources and assessing performance of the Company. The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Application (\u201cANDA\u201d) and products whose marketing approvals were secured via a New Drug Application (\u201cNDA\u201d). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals.",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company\u2019s condensed unaudited consolidated financial statements. Please see Note 15 for further details.",
            "type": "paragraph"
        },
        {
            "id": 10,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nRevenue Recognition The Company generates revenue from manufacturing and licensing fees and sales of generic pharmaceuticals bearing the Elite label to pharmaceutical distributors for pharmacies and institutions. Manufacturing fees include the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, through the manufacture of formulations and the development of new products. Revenues earned from the sale of Elite label products are recorded at their net realizable value which consists of gross amounts invoiced reduced by contractual reductions, including, without limitation, chargebacks, discounts and program rebates, as applicable. Licensing fees include the commercialization of products either by license and the collection of royalties, or the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations.",
            "type": "paragraph"
        },
        {
            "id": 11,
            "context": "Under ASC 606, Revenue from Contacts with Customers (\u201cASC 606\u201d), the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "Nature of goods and services\nThe following is a description of the Company\u2019s goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable:\na) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if, and when, the products are approved. These products include products using controlled-release drug technology. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release pharmaceutical products.",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "The Company recognizes revenue when the customer obtains control of the Company\u2019s product based on the contractual shipping terms of the contract, at which time the performance obligation is deemed to be completed. The Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer.",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales.",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will recognize revenue from the milestone when there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED) Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company\u2019s contracts contained a significant financing component as of December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 19,
            "context": "In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer\u2019s products occurs.\nc) Sale of product under the Elite label The Company began direct sales of products under the Company\u2019s own label on April 1, 2023. License agreements will remain in place for select products. With this transition, however, a large portion of the manufacturing and license fees now reported will be replaced with revenues from sales of Elite labeled pharmaceutical products to distributors for pharmacies and institutions.",
            "type": "paragraph"
        },
        {
            "id": 20,
            "context": "The Company recognizes revenue when the customer obtains control of the Company\u2019s product based on the contractual shipping terms, at which time the performance obligation is deemed to be completed. The Company is primarily responsible for fulfilling the promise to deliver the product and bears risk of loss while the inventory is in-transit to the purchaser. Revenue is measured as the amount of consideration earned from the sale of Elite labeled pharmaceutical products are recorded at their net realizable value which consists of gross amounts invoiced reduced by contractual reductions, including, without limitation, chargebacks, discounts and program rebates, as applicable.",
            "type": "paragraph"
        },
        {
            "id": 21,
            "context": "Disaggregation of revenue\nIn the following table, revenue is disaggregated by type of revenue generated by the Company. The Company recognizes revenue at a point in time for all performance obligations. The table also includes a reconciliation of the disaggregated revenue with the reportable segments:\nSCHEDULE OF DISAGGREGATION OF REVENUE\n\n| For the Three Months Ended December 31, | For the Nine Months Ended December 31, |\n| 2023 | 2022 | 2023 | 2022 |\n| NDA: |\n| Manufacturing fees | $ | - | $ | - | $ | - | $ | - |\n| Licensing fees | $ | \u2014 | $ | \u2014 | $ | \u2014 | $ | \u2014 |\n| Total NDA revenue | \u2014 | \u2014 | \u2014 | \u2014 |\n| ANDA: |\n| Manufacturing fees | $ | 14,791,110 | $ | 7,798,159 | $ | 36,208,217 | $ | 21,312,663 |\n| Licensing fees | 747,690 | 1,451,907 | 2,467,844 | 4,200,888 |\n| Total ANDA revenue | 15,538,800 | 9,250,066 | 38,676,061 | 25,513,551 |\n| Total revenue | $ | 15,538,800 | $ | 9,250,066 | $ | 38,676,061 | $ | 25,513,551 |",
            "type": "table"
        },
        {
            "id": 22,
            "context": "Selected information on reportable segments and reconciliation of operating income by segment to income from operations before income taxes are disclosed within Note 15.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nCash\nCash consists of cash on deposit with banks and money market instruments. The Company places its cash with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances.\nRestricted Cash As of December 31, 2023, and March 31, 2023, the Company had $ 427,999 and $ 412,434 , of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority (\u201cNJEDA\u201d) bonds (see Note 5).",
            "type": "paragraph"
        },
        {
            "id": 23,
            "context": "Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable are comprised of balances due from customers, net of estimated allowances for expected credit losses, and other contractual deductions, including, without limitation, chargebacks, discounts and program rebates. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances.",
            "type": "paragraph"
        },
        {
            "id": 24,
            "context": "The allowance for expected credit losses is based on the probability of future collection under the current expected credited loss (\u201cCECL\u201d) impairment model under Accounting Standards Update (\u201cASU\u201d) 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Assets, which was adopted by the Company on April 1, 2023, as discussed below within Recently Adopted Accounting Pronouncements. Under the CECL impairment model, the Company determines its allowance by applying a loss-rate method based on an aging schedule using the Company\u2019s historical loss rate. The Company also considers reasonable and supportable current information in determining its estimated loss rates, such as external forecasts, macroeconomic trends or other factors including customers\u2019 credit risk and historical loss experience. The adequacy of the allowance is evaluated on a regular basis. Account balances are written off after all means of collection are exhausted and the balance is deemed uncollectible. Subsequent recoveries are credited to the allowance. Changes in the allowance are recorded as adjustments to credit losses in the period incurred.",
            "type": "paragraph"
        },
        {
            "id": 25,
            "context": "Prior to April 1, 2023, trade receivables were presented net of allowance for expected credit losses based on the credit risk of specific clients, past collection history, and management\u2019s evaluation of other risks. Expected credit losses stemming from unbilled receivables expected to be billed between March 31, 2024 and March 31, 2028 include additional risk premiums estimated based on factors such as projected inflation, projected decreases in GDP, and projected unemployment.",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "Inventory\nInventory is recorded at the lower of cost or net realizable value on specific identification by lot number basis.\nLong-Lived Assets\nThe Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable. Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently.",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income.\nIntangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly.",
            "type": "paragraph"
        },
        {
            "id": 28,
            "context": "The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company\u2019s expected future cash flows; a sustained, significant decline in the Company\u2019s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company\u2019s segments; unanticipated competition; and slower growth rates.",
            "type": "paragraph"
        },
        {
            "id": 29,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED) During the year ended March 31, 2023, the Company determined indicators of impairment occurred and recorded impairment expense of $ 292,807 on its ANDAs and patents. There were no such impairments recorded during the period ended December 31, 2023. The Company notes that none of its patents relate to any of the Company\u2019s revenue producing activities.",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "The following table summarizes the Company\u2019s intangible assets as of and for the periods ended December 31, 2023 and March 31, 2023:\nSCHEDULE OF INTANGIBLE ASSETS\n\n| December 31, 2023 |\n| Estimated Useful Life | Gross Carrying Amount | Impairment losses | Accumulated Amortization | Net Book Value |\n| Patent application costs | * | $ | 289,039 | $ | \u2014 | $ | \u2014 | $ | 289,039 |\n| ANDA acquisition costs | Indefinite | 6,052,189 | \u2014 | \u2014 | 6,052,189 |\n| $ | 6,341,228 | $ | \u2014 | $ | \u2014 | $ | 6,341,228 |",
            "type": "table"
        },
        {
            "id": 31,
            "context": "| March 31, 2023 |\n| Estimated Useful Life | Gross Carrying Amount | Impairment losses | Accumulated Amortization | Net Book Value |\n| Patent application costs | * | $ | 465,684 | $ | ( 176,645 | ) | $ | \u2014 | $ | 289,039 |\n| ANDA acquisition costs | Indefinite | 6,168,351 | ( 116,162 | ) | \u2014 | 6,052,189 |\n| $ | 6,634,035 | $ | ( 292,807 | ) | $ | \u2014 | $ | 6,341,228 |",
            "type": "table"
        },
        {
            "id": 32,
            "context": "Research and Development\nResearch and development expenditures are charged to expenses as incurred.\nContingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company\u2019s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic Oxycontin and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. Elite obtained agreement with Purdue to stay the litigation for six months. Elite\u2019s launch of a generic Oxycontin will depend on the approval by the FDA and the outcome of various litigations involving Purdue or the expiry of the patents listed on the Orange Book. As of December 31, 2023, the results of such proceedings cannot be predicted with certainty, but the Company does not anticipate that the final outcome, if any, arising out of any such matters will have a material adverse effect on its business, financial condition or results of operations.",
            "type": "paragraph"
        },
        {
            "id": 34,
            "context": "Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future.",
            "type": "paragraph"
        },
        {
            "id": 35,
            "context": "The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution .",
            "type": "paragraph"
        },
        {
            "id": 36,
            "context": "The Company operates in multiple tax jurisdictions within the United States of America. The Company remains subject to examination in all tax jurisdiction until the applicable statutes of limitation expire. As of December 31, 2023, a summary of the tax years that remain subject to examination in our major tax jurisdictions are: United States \u2013 Federal, 2016 and forward. The Company did not record unrecognized tax positions for the nine months ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 37,
            "context": "Warrants and Preferred Shares The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt, ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, as applicable. Each feature of a freestanding financial instrument including, without limitation, any rights relating to subsequent dilutive issuances, dividend issuances, equity sales, rights offerings, forced conversions, optional redemptions, automatic monthly conversions, dividends and exercise is assessed with determinations made regarding the proper classification in the Company\u2019s financial statements.",
            "type": "paragraph"
        },
        {
            "id": 38,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nStock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The cost of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for forfeitures as they occur.",
            "type": "paragraph"
        },
        {
            "id": 39,
            "context": "In accordance with the Company\u2019s Director compensation policy and certain employment contracts, director\u2019s fees and a portion of employee\u2019s salaries are to be paid via the issuance of shares of the Company\u2019s Common Stock (\u201cCommon Stock\u201d), in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the average closing price of the Company\u2019s Common Stock. The Company records earned but unissued stock-based compensation in accrued expenses.",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "Sale of ANDA During the quarter ended December 31, 2022, the Company entered into an agreement with Pyros Pharmaceuticals, Inc. (\u201cPyros\u201d) pursuant to which the Company sold to Pyros its rights in and to the Company\u2019s approved abbreviated new drug applications (ANDAs) for its generic Sabril drug (the \u201cSabril Product\u201d). The Company sold its rights to Pyros for $ 1,000,000 , which was recorded as gain on sale of ANDA during the year ended March 31, 2023. There is no further action required by the Company regarding the rights which would affect future periods.",
            "type": "paragraph"
        },
        {
            "id": 41,
            "context": "In conjunction with the sale of its Sabril Product to Pyros, the Company executed a Manufacturing and Supply Agreement (the \u201cPyros Agreement\u201d) with Pyros. Under the terms of the Pyros Agreement, the Company will receive an agreed-upon price per drug for the manufacturing and packaging of Sabril over a term of three years. Revenue per the Pyros Agreement will be recognized as control of the manufactured and supplied drugs is transferred to Pyros (at the time of delivery).",
            "type": "paragraph"
        },
        {
            "id": 42,
            "context": "Earnings Per Share Attributable to Common Shareholders\u2019 The Company follows ASC 260, Earnings Per Share, which requires presentation of basic and diluted earnings per share (\u201cEPS\u201d) on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings per share is computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The computation of diluted net income per share does not include the change in fair value of derivative instruments or the conversion of securities that would have an antidilutive effect.",
            "type": "paragraph"
        },
        {
            "id": 43,
            "context": "As the average market price of Common Stock for the three and nine months ended December 31, 2023 and 2022 did not exceed the exercise price of the warrants, the potential dilution from the warrants converting into 79,008,661 shares of Common Stock for all periods have been excluded from the number of shares used in calculating diluted net income per share as their inclusion would have been antidilutive.",
            "type": "paragraph"
        },
        {
            "id": 44,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nThe following is the computation of earnings per share applicable to common shareholders for the periods indicated:\nSCHEDULE OF EARNINGS (LOSS) PER SHARE APPLICABLE TO COMMON SHAREHOLDERS\n\n| For the Three Months Ended December 31, | For the Nine Months Ended December 31, |\n| 2023 | 2022 | 2023 | 2022 |\n| Numerator |\n| Net income - basic | $ | 706,354 | $ | 2,970,078 | $ | 16,782,764 | $ | 4,791,100 |\n| Effect of dilutive instrument on net income | \u2014 | 372,894 | \u2014 | 561,070 |\n| Net income - diluted | $ | 706,354 | $ | 3,342,972 | $ | 16,782,764 | $ | 5,352,170 |\n| Denominator |\n| Weighted average shares of Common Stock outstanding - basic | 1,014,768,071 | 1,013,915,081 | 1,014,265,162 | 1,012,480,115 |\n| Dilutive effect of stock options and convertible securities | 9,680,374 | \u2014 | 5,246,651 | \u2014 |\n| Weighted average shares of Common Stock outstanding - diluted | 1,024,448,445 | 1,013,915,081 | 1,019,511,813 | 1,012,480,115 |\n| Net income per share |\n| Basic | $ | 0.00 | $ | 0.00 | $ | 0.02 | $ | 0.00 |\n| Diluted | $ | 0.00 | $ | 0.00 | $ | 0.02 | $ | 0.01 |",
            "type": "table"
        },
        {
            "id": 45,
            "context": "Fair Value of Financial Instruments\nASC 820, Fair Value Measurements and Disclosures (\u201cASC 820\u201d) provides a framework for measuring fair value in accordance with generally accepted accounting principles. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity\u2019s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).",
            "type": "paragraph"
        },
        {
            "id": 46,
            "context": "The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described as follows:",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "| \u25cf | Level 1 \u2013 Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. |\n| \u25cf | Level 2 \u2013 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |\n| \u25cf | Level 3 \u2013 Inputs that are unobservable for the asset or liability. |",
            "type": "table"
        },
        {
            "id": 48,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nMeasured on a Recurring Basis\nThe following table presents information about our liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fell:\nSCHEDULE OF LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS\n\n| Fair Value Measurement |\n| Amount at Fair Value | Level 1 | Level 2 | Level 3 |\n| Balance as of April 1, 2023 | $ | 521,711 | $ | \u2014 | $ | \u2014 | $ | 521,711 |\n| Change in fair value of derivative financial instruments - warrants | 5,075,489 | \u2014 | \u2014 | 5,075,489 |\n| Balance as of December 31, 2023 | $ | 5,597,200 | $ | \u2014 | $ | \u2014 | $ | 5,597,200 |",
            "type": "table"
        },
        {
            "id": 49,
            "context": "| Fair Value Measurement |\n| Amount at Fair Value | Level 1 | Level 2 | Level 3 |\n| Balance as of April 1, 2022 | $ | 936,837 | $ | \u2014 | $ | \u2014 | $ | 936,837 |\n| Change in fair value of derivative financial instruments - warrants | ( 561,070 | ) | \u2014 | \u2014 | ( 561,070 | ) |\n| Balance as of December 31, 2022 | $ | 375,767 | $ | \u2014 | $ | \u2014 | $ | 375,767 |",
            "type": "table"
        },
        {
            "id": 50,
            "context": "See Note 11 for specific inputs used in determining fair value. The carrying amounts of the Company\u2019s financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value.",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "Non-Financial Assets that are Measured at Fair Value on a Non-Recurring Basis\nNon-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented.\nFinancial Instruments \u2014 Credit Losses (ASU 2016-13) In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (\u201cCECL\u201d). The amendments in this update introduce a new accounting model to measure credit losses for financial assets measured at amortized cost. The FASB has also issued additional ASUs to clarify the scope and provide additional guidance for ASU 2016-13. Credit losses for financial assets measured at amortized cost should be determined based on the total current expected credit losses over the life of the financial asset or group of financial assets. In effect, the financial asset or group of financial assets should be presented at the net amount expected to be collected. Credit losses will no longer be recorded under the current incurred loss model for financial assets measured at amortized cost. The amendments also modify the accounting for available-for-sale debt securities whereby credit losses will be recorded through an allowance for credit losses rather than a write-down to the security\u2019s cost basis, which allows for reversals of credit losses when estimated credit losses decline. Credit losses for available-for-sale debt securities should be measured in a manner similar to current GAAP.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "The amendments were effective on April 1, 2023 for the Company, and must be applied using a modified retrospective approach with a cumulative-effect adjustment through retained earnings as of the beginning of the fiscal year upon adoption as required. While the standard modifies the measurement of the allowance for credit losses, it does not alter the credit risk of our trade or unbilled receivables.",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "The impact of applying the CECL methodology upon adoption effective on April 1, 2023 was immaterial to the Company\u2019s consolidated financial statements. The Company\u2019s quantitative allowance for credit loss estimates under CECL was determined using the loss rate method, which is impacted by certain forecasted economic factors. In addition to the Company\u2019s quantitative allowance for credit losses, the Company also incorporates qualitative adjustments that may relate to unique risks, changes in current economic conditions that may not be reflected in quantitatively derived results, or other relevant factors to further inform the Company\u2019s estimate of the allowance for credit losses.",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED) Additionally, due to the expansion of the time horizon over which the Company is required to estimate future credit losses, the Company may experience increased volatility in its future provisions for credit losses. Factors that could contribute to such volatility include, but are not limited to, changes in the composition and credit quality of customer base, economic conditions and forecasts, the allowance for credit loss models that are used, the data that is included in the models, the associated qualitative allowance framework, and the Company\u2019s estimation techniques.",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "The Company has had no recordable write offs for bad debts or uncollectible invoiced amounts during the for the nine months ended December 31, 2023 or the prior twelve months ended March 31, 2023. In applying the CECL methodology, the Company recorded an estimated allowance of $ 194,600 for current estimated credit losses.",
            "type": "paragraph"
        },
        {
            "id": 56,
            "context": "Treasury Stock\nThe Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders\u2019 equity.\nRecently Issued Accounting Pronouncements\nManagement has evaluated recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.\nNOTE 2. INVENTORY\nInventory consisted of the following:\nSCHEDULE OF INVENTORY\n\n| December 31, 2023 | March 31, 2023 |\n| Finished goods | $ | 5,544,848 | $ | 2,352,330 |\n| Work-in-progress | 1,247,307 | 1,791,311 |\n| Raw materials | 7,532,886 | 5,407,075 |\n| Inventory | $ | 14,325,041 | $ | 9,550,716 |",
            "type": "table"
        },
        {
            "id": 57,
            "context": "NOTE 3. PROPERTY AND EQUIPMENT, NET\nProperty and equipment consisted of the following:\nSCHEDULE OF PROPERTY AND EQUIPMENT\n\n| December 31, 2023 | March 31, 2023 |\n| Land, building and improvements | $ | 10,269,297 | $ | 10,768,181 |\n| Laboratory, manufacturing, warehouse and transportation equipment | 14,518,570 | 13,364,512 |\n| Office equipment and software | 373,601 | 395,563 |\n| Furniture and fixtures | 512,032 | 484,237 |\n| Property and equipment, gross | 25,673,500 | 25,012,493 |\n| Less: Accumulated depreciation | ( 15,578,471 | ) | ( 14,586,335 | ) |\n| Property and equipment, net | $ | 10,095,029 | $ | 10,426,158 |",
            "type": "table"
        },
        {
            "id": 58,
            "context": "Depreciation expense was $ 336,614 and $ 314,610 for the three months ended December 31, 2023 and 2022, respectively, and $ 992,136 and $ 923,365 for the nine months ended December 31, 2023 and 2022, respectively.",
            "type": "paragraph"
        },
        {
            "id": 59,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 4. ACCRUED EXPENSES\nAs of December 31, 2023 and March 31, 2023, the Company\u2019s accrued expenses consisted of the following:\nSUMMARY OF ACCRUED EXPENSES\n\n| December 31, 2023 | March 31, 2023 |\n| Salaries and fees payable in Common Stock inclusive of the change in fair value of Common stock underlying such liabilities | $ | 6,934,812 | $ | 4,125,000 |\n| Income tax | \u2014 | 414,989 |\n| Co-development profit split | 3,389,949 | \u2014 |\n| Consultant contract fees | 10,000 | 193,333 |\n| Audit fees | 125,000 | 125,000 |\n| Director dues | 22,500 | 70,000 |\n| Legal and professional expense | 75,000 | \u2014 |\n| Employee bonuses | 712,384 | \u2014 |\n| Other accrued expenses | 615,000 | 119,404 |\n| Total accrued expenses | $ | 11,884,645 | $ | 5,047,726 |",
            "type": "table"
        },
        {
            "id": 60,
            "context": "NOTE 5. NJEDA BONDS In relation to the Series A Notes, the Company is required to maintain a debt service reserve. The debt service reserve is classified as restricted cash on the accompanying unaudited consolidated balance sheets. The NJEDA Bonds require the Company to make an annual principal payment on September 1st based on the amount specified in the loan documents and semi-annual interest payments on March 1st and September 1st, equal to interest due on the outstanding principal. The annual interest rate on the Series A Note is 6.5 %. The NJEDA Bonds are collateralized by a first lien on the Company\u2019s facility and equipment acquired with the proceeds of the original and refinanced bonds.",
            "type": "paragraph"
        },
        {
            "id": 61,
            "context": "The following tables summarize the Company\u2019s bonds payable liability:\nSCHEDULE OF BONDS PAYABLE LIABILITY\n\n| December 31, 2023 | March 31, 2023 |\n| Gross bonds payable |\n| NJEDA Bonds - Series A Notes | $ | 1,120,000 | $ | 1,245,000 |\n| Less: Current portion of bonds payable (prior to deduction of bond offering costs) | ( 130,000 | ) | ( 125,000 | ) |\n| Long-term portion of bonds payable (prior to deduction of bond offering costs) | $ | 990,000 | $ | 1,120,000 |\n| Bond offering costs | $ | 354,454 | $ | 354,454 |\n| Less: Accumulated amortization | ( 259,930 | ) | ( 249,294 | ) |\n| Bond offering costs, net | $ | 94,524 | $ | 105,160 |\n| Current portion of bonds payable - net of bond offering costs |\n| Current portions of bonds payable | $ | 130,000 | $ | 125,000 |\n| Less: Bonds offering costs to be amortized in the next 12 months | ( 14,178 | ) | ( 14,178 | ) |\n| Current portion of bonds payable, net of bond offering costs | $ | 115,822 | $ | 110,822 |\n| Long term portion of bonds payable - net of bond offering costs |\n| Long term portion of bonds payable | $ | 990,000 | $ | 1,120,000 |\n| Less: Bond offering costs to be amortized subsequent to the next 12 months | ( 80,346 | ) | ( 90,982 | ) |\n| Long term portion of bonds payable, net of bond offering costs | $ | 909,654 | $ | 1,029,018 |",
            "type": "table"
        },
        {
            "id": 62,
            "context": "Amortization expense was $ 3,540 and $ 3,544 for the three months ended December 31, 2023 and 2022, $ 10,636 and $ 10,629 for the nine months ended December 31, 2023 and 2022, respectively. Interest payable was $ 24,267 and $ 6,744 as of December 31, 2023 and March 31, 2023, respectively. Interest expense was $ 18,200 and $ 20,231 for the three months ended December 31, 2023 and 2022, respectively, and $ 57,985 and $ 63,808 for the nine months ended December 31, 2023 and 2022, respectively.",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nMaturities of bonds for the next five years, exclusive of the nine months ended December 31, 2023 are as follows:\nSCHEDULE OF MATURITIES OF BONDS\n\n| Years ending March 31, | Amount |\n| 2024 | $ | \u2014 |\n| 2025 | 130,000 |\n| 2026 | 140,000 |\n| 2027 | 150,000 |\n| 2028 | 160,000 |\n| Thereafter | 540,000 |\n| Total | $ | 1,120,000 |",
            "type": "table"
        },
        {
            "id": 64,
            "context": "NOTE 6. LOANS PAYABLE On April 2, 2022, the Company and Elite Labs entered into a Loan and Security Agreement (the \u201cEWB Loan Agreement\u201d) with East West Bank (\u201cEWB\u201d). Pursuant to the EWB Loan Agreement, the Company and Elite Labs received one term loan for a principal amount of $ 12,000,000 (the \u201cEWB Term Loan\u201d) and a revolving line of credit up to $ 2,000,000 (the \u201cEWB Revolver,\u201d together with the \u201cEWB Term Loan,\u201d the \u201cEWB Loans\u201d), each of which shall be used for working capital. The EWB Term Loan bears interest at a rate of 9.73 % ( 1.73 % plus the prime rate (\u201cPrime\u201d)) and is repayable over five years , maturing on May 1, 2027 . The EWB Revolver bears interest at a rate of ( 8.87 % ( 0.87 % plus Prime)) and matures on May 1, 2027 . The total transaction costs associated with the EWB Term Loan incurred as of March 31, 2023, were $ 40,120 , which are being amortized on a monthly basis over five years, beginning in April 2022. The EWB Loans are secured by a security interest in the personal property of the Company and Elite Labs. The EWB Loan Agreement contains customary representations, warranties and covenants. These covenants include, but are not limited to, maintaining maximum leverage ratios of 3.50 to 1.00, minimum liquidity of $5,000,000, minimum cash of $1,000,000, a fixed charge coverage ratio of 1.25 to 1.00 and restrictions on mergers or sales of assets and debt borrowings . As of March 31, 2023, the principal and interest on the EWB Term Loan has been paid in full by the Company and the EWB Loan Agreement is terminated.",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "In place of the EWB Term Loan, the Company has entered into a collateralized promissory note with individual lenders with rates comparable to the EWB Term Loan but with less restrictive covenants (a \u201cPromissory Note\u201d). As of June 2, 2023, a Promissory Note was placed with Nasrat Hakim, CEO and Chairman of the Board of Directors, for $ 3,000,000 . The Promissory Note has an interest rate of 9 % for the first year and 10 % for an optional second year and the proceeds will be used for working capital and other business purposes.",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "Loans payable consisted of the following:\nSCHEDULE OF LOANS PAYABLE\n\n| December 31, 2023 | March 31, 2023 |\n| Mortgage loan payable 4.75 % interest and maturing June 2032 | $ | 2,438,958 | $ | 2,472,923 |\n| Equipment and insurance financing loans payable, between 7.10 % and 12.02 % interest and maturing between January 2024 and October 2025 | 158,726 | 259,611 |\n| Less: Current portion of loans payable | ( 190,607 | ) | ( 200,032 | ) |\n| Long-term portion of loans payable | $ | 2,407,077 | $ | 2,532,502 |",
            "type": "table"
        },
        {
            "id": 67,
            "context": "The interest expense associated with the loans payable was $ 30,384 and $ 317,844 for the three months ended December 31, 2023 and 2022, and $ 101,478 and $ 579,109 for the nine months ended December 31, 2023 and 2022, respectively.",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nLoan principal payments for the next five years are as follows:\nSCHEDULE OF LOAN PRINCIPAL PAYMENTS\n\n| Future principal balances |\n| Years ending March 31, | Amount |\n| 2024 (excluding the nine months ended December 31, 2023) | $ | 44,535 |\n| 2025 | 186,657 |\n| 2026 | 120,748 |\n| 2027 | 92,773 |\n| 2028 | 94,433 |\n| 2029 and thereafter | 2,058,538 |\n| Total remaining principal balance | $ | 2,597,684 |",
            "type": "table"
        },
        {
            "id": 69,
            "context": "NOTE 7. RELATED PARTY LOANS The Company has entered into a collateralized promissory note with individual lenders with rates comparable to the EWB Term Loan but with fewer covenants (the \u201cHakim Promissory Note\u201d). These covenants include filing timely tax returns and financial statements, and an agreement not to sell, lease, or transfer a substantial portion of the Company\u2019s assets during the term of the Hakim Promissory Note. On June 2, 2023, the Company entered into a Promissory Note with Nasrat Hakim, CEO and Chairman of the Board of Directors, pursuant to which the Company borrowed funds in the aggregate principal amount of $ 3,000,000 . The Hakim Promissory Note has an interest rate of 9 % for the first year and 10 % for an optional second year and the proceeds will be used for working capital and other business purposes. The original maturity date of the Hakim Promissory Note is June 2, 2024, with an optional second year extension. The second year extension must be exercised by both parties 60 days prior to the original maturity date. As of the date of this filing, the Company does not expect to exercise the second year extension. For the three and nine months ended December 31, 2023, interest expense on the Hakim Promissory Note totaled $ 67,500 and $ 202,500 respectively, recorded on the Condensed Consolidated Balance Sheets in accrued expenses and on the Condensed Consolidated Statements of Operations in interest expense and amortization of debt issuance costs.",
            "type": "paragraph"
        },
        {
            "id": 70,
            "context": "On July 1, 2022, the EWB provided a mortgage loan (\u201cEWB Mortgage Loan\u201d) in the amount of $ 2.55 million for the purchase of the property at 135-137 Ludlow Avenue, which was formerly a lease held by the Company. The EWB Mortgage Loan matures in 10 years and bears interest at a rate of 4.75% fixed for 5 years then adjustable at the Wall Street Journal Prime Rate (\u201cWSJP\u201d) plus 0.5% with floor rate of 4.5% . The total transaction costs associated with the EWB Mortgage Loan incurred as of December 31, 2023, were $ 13,251 , which are being amortized on a monthly basis over ten years, beginning in July 2022. The EWB Mortgage Loan contains customary representations, warranties and covenants. These covenants include maintaining a minimum debt coverage ratio of 1.50 to 1.00 tested annually and a minimum trailing 12-month debt coverage ratio of 1.50 to 1.00. As of the date of this filing, the Company was in compliance with each financial covenant .",
            "type": "paragraph"
        },
        {
            "id": 71,
            "context": "On June 30, 2023, the Company entered into a collateralized promissory note with Davis Caskey (the \u201cCaskey Promissory Note\u201d). The Caskey Promissory Note has a principal balance of $ 1,000,000 and an interest rate of 9 % for the first year and 10 % for an optional second year. The Caskey Promissory Note is subject to the same covenants as are contained in the Hakim Promissory Note. The proceeds will be used for working capital and other business purposes. The original maturity date of the Caskey Promissory Note is June 30, 2024, with an optional second year extension. The second year extension must be exercised by both parties 60 days prior to the original maturity date. As of the date of this filing, the Company does not expect to exercise the second year extension. For the three and nine months ended December 31, 2023, interest expense on the Caskey Promissory Note totaled $ 22,500 and $ 67,500 respectively, recorded on the Condensed Consolidated Balance Sheets in accrued expenses and on the Condensed Consolidated Statements of Operations in interest expense and amortization of debt issuance costs.",
            "type": "paragraph"
        },
        {
            "id": 72,
            "context": "NOTE 8. DEFERRED REVENUE Deferred revenues in the aggregate amount of $ 22,222 as of December 31, 2023, were comprised of a current component of $ 13,333 and a long-term component of $ 8,889 . Deferred revenues in the aggregate amount of $ 32,223 as of March 31, 2023, were comprised of a current component of $ 13,333 and a long-term component of $ 18,890 . These amounts represent the unamortized balance of a $ 200,000 advance payment received for a TAGI Pharma licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025 . These advance payments were recorded as deferred revenue when received and are earned, on a straight-line basis over the life of the licenses. The current component is equal to the amount of revenue to be earned during the 12-month period immediately subsequent to the balance sheet date and the long-term component is equal to the amount of revenue to be earned thereafter.",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 9. COMMITMENTS AND CONTINGENCIES Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company\u2019s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.",
            "type": "paragraph"
        },
        {
            "id": 74,
            "context": "On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic Oxycontin and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. Elite obtained agreement with Purdue to stay the litigation for six months. Elite\u2019s launch of a generic Oxycontin will depend on the approval by the FDA and the outcome of various litigations involving Purdue or the expiry of the patents listed on the Orange Book. As of December 31, 2023, the results of such proceedings cannot be predicted with certainty, but the Company does not anticipate that the final outcome, if any, arising out of any such matters will have a material adverse effect on its business, financial condition or results of operations.",
            "type": "paragraph"
        },
        {
            "id": 75,
            "context": "Operating Leases The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the \u201cLudlow Ave. lease\u201d) which began in 2010. On June 30, 2021, the Company exercised a renewal option, with such option including a term that begins on January 1, 2022 and expires on December 31, 2026. The Ludlow Ave. lease was terminated on July 1, 2022, when the Company purchased the underlying property.",
            "type": "paragraph"
        },
        {
            "id": 76,
            "context": "In October 2020, the Company entered into an operating lease for office space in Pompano Beach, Florida (the \u201cPompano Office Lease\u201d). The Pompano Office Lease is for approximately 1,275 square feet of office space, with Elite taking occupancy on November 1, 2020. The Pompano Office Lease had a term of three years, ending on October 31, 2023. The Pompano Office Lease was extended for one additional year to October 31, 2024.",
            "type": "paragraph"
        },
        {
            "id": 77,
            "context": "The Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company has elected to account for non-lease components associated with its leases and lease components as a single lease component.",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "The Company recognizes a right-of-use asset, which represents the Company\u2019s right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company\u2019s obligation to make payments arising over the lease term. The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing rate.",
            "type": "paragraph"
        },
        {
            "id": 79,
            "context": "Finance Leases In November 2023, the Company entered into an finance lease for equipment (the \u201cWaters Equipment Lease\u201d). The Waters Equipment Lease is related to lab equipment with an acquisition cost of $ 499,775 , with Elite taking ownership of the asset on December 1, 2023. The Waters equipment lease has a term of five years, ending on November 29, 2028. The Company also has the option to purchase the asset at the end of the lease term for the amount of $ 1 , which is probable to be exercised.",
            "type": "paragraph"
        },
        {
            "id": 80,
            "context": "A lease is classified as a finance lease if any of the following criteria are met: (i) ownership of the underlying asset transfers to the Company by the end of the lease term; (ii) the lease contains an option to purchase the underlying asset that the Company is reasonably expected to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of lease payments and any residual value guaranteed by the Company equals or exceeds substantially all of the fair value of the underlying asset; or (v) the underlying asset is of a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. A lease that does not meet any of the criteria to be classified as a finance lease is classified as an operating lease. As the Company expects to exercise the option to purchase the asset at the end of the lease term, the Waters equipment lease was determined to be a finance lease. The finance lease is included on the balance sheets as Finance lease - right-of-use asset and Lease obligation - finance lease. The finance lease costs are split between Depreciation and amortization expense related to the asset and Interest expense and amortization of debt issuance costs on the lease liability, using the effective rate charged by the lessor. The Company has elected to account for lease and non-lease components separately.",
            "type": "paragraph"
        },
        {
            "id": 81,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nLease assets and liabilities are classified as follows on the condensed consolidated balance sheet:\nSCHEDULE OF LEASE ASSETS AND LIABILITIES\n\n| Lease | Classification | December 31, 2023 |\n| Assets |\n| Finance | Finance lease \u2013 right-of-use asset | $ | 408,428 |\n| Operating | Operating lease \u2013 right-of-use asset | 26,231 |\n| Total leased assets | $ | 434,659 |\n| Liabilities |\n| Current |\n| Finance | Lease obligation \u2013 finance lease | $ | 37,444 |\n| Operating | Lease obligation \u2013 operating lease | 26,231 |\n| Long-term |\n| Finance | Lease obligation \u2013 finance lease, net of current portion | 200,939 |\n| Operating | Lease obligation \u2013 operating lease, net of current portion | \u2014 |\n| Total lease liabilities | $ | 264,614 |",
            "type": "table"
        },
        {
            "id": 82,
            "context": "Rent expense is recorded on the straight-line basis. Rent expense under the 135 Ludlow Ave. modified lease was $ 0 for the three months ended December 31, 2023 and 2022, respectively, and $ 0 and $ 58,248 for the nine months ended December 31, 2023 and 2022, respectively. Rent expense under the Pompano Office Lease for the three months ended December 31, 2023 and 2022 was $ 7,565 and $ 6,456 , respectively, and $ 20,603 and $ 19,116 for the nine months ended December 31, 2023 and 2022, respectively. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations.",
            "type": "paragraph"
        },
        {
            "id": 83,
            "context": "The table below shows the future minimum rental payments, exclusive of taxes, insurance and other costs, under the Pompano Office Lease and Waters Equipment Lease:\nSCHEDULE OF FUTURE MINIMUM RENTAL PAYMENTS\n\n| Years ending March 31, | Operating Lease Amount | Financing Lease Amount | Total |\n| 2024 (excluding the nine months ended December 31, 2023) | $ | 8,087 | $ | 16,286 | $ | 24,373 |\n| 2025 | 18,870 | 65,145 | 84,015 |\n| 2026 | \u2014 | 65,145 | 65,145 |\n| 2027 | \u2014 | 65,145 | 65,145 |\n| 2028 | \u2014 | 65,145 | 65,145 |\n| Thereafter | \u2014 | 43,429 | 43,429 |\n| Less: interest | ( 727 | ) | ( 81,911 | ) | ( 82,638 | ) |\n| Present value of lease payments | $ | 26,230 | $ | 238,384 | $ | 264,614 |",
            "type": "table"
        },
        {
            "id": 84,
            "context": "The weighted-average remaining lease term and the weighted-average discount rate of our leases were as follows:\nSCHEDULE OF WEIGHTED -AVERAGE REMAINING TERM AND THE WEIGHTED-AVERAGE DISCOUNT RATE\n\n| Lease Term and Discount Rate | December 31, 2023 |\n| Remaining lease term (years) |\n| Operating leases | 0.8 |\n| Finance leases | 4.9 |\n| Discount rate |\n| Operating leases | 6.0 | % |\n| Finance leases | 12.5 | % |",
            "type": "table"
        },
        {
            "id": 85,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 10. PREFERRED STOCK\nSeries J convertible preferred stock On April 28, 2017, the Company created the Series J Convertible Preferred Stock (\u201cSeries J Preferred\u201d) in conjunction with the Certificate of Designations. A total of 50 shares of Series J Preferred were authorized, zero shares are issued and outstanding, with a stated value of $ 1,000,000 per share and a par value of $ 0.01 .",
            "type": "paragraph"
        },
        {
            "id": 86,
            "context": "NOTE 11. DERIVATIVE FINANCIAL INSTRUMENTS \u2013 WARRANTS\nThe Company evaluates and accounts for its freestanding instruments in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities.\nThe Company issued warrants, with a term of ten years, to affiliates in connection with an exchange agreement dated April 28, 2017, as further described in this note below.\nThe Company has 79,008,661 total warrants to purchase shares of Common Stock outstanding with a weighted average exercise price of $ 0.1521 as of December 31, 2023 and March 31, 2023. On April 28, 2017, the Company entered into an Exchange Agreement with Hakim, the Chairman of the Board, President, and Chief Executive Officer of the Company, pursuant to which the Company issued to Hakim 24.0344 shares of its Series J Preferred and warrants to purchase an aggregate of 79,008,661 shares of its Common Stock (the \u201cSeries J Warrants\u201d and, along with the Series J Preferred issued to Hakim, the \u201cSecurities\u201d) in exchange for 158,017,321 shares of Common Stock owned by Hakim. The fair value of the Series J Warrants was determined to be $ 6,474,674 upon issuance at April 28, 2017.",
            "type": "paragraph"
        },
        {
            "id": 87,
            "context": "The Series J Warrants are exercisable for a period of 10 years from the date of issuance, commencing April 28, 2020. The initial exercise price is $ 0.1521 per share and the Series J Warrants can be exercised for cash or on a cashless basis, including a provision within that provides the holder a choice of net cash settlement or settlement in shares upon a cashless exercise. The net cash settlement amount is the cash value obtained by subtracting the then exercise price from the closing price of the Company\u2019s Common Stock (provided such closing price is higher than the exercise price) and multiplying the difference by the number of shares exercised. As this event is at the holder\u2019s option, it is considered outside of the Company\u2019s control. As a result of the net cash settlement at the option of the holder, such warrants are classified as liabilities and measured initially and subsequently at fair value.",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "The exercise price is subject to adjustment for any issuances or deemed issuances of Common Stock or Common Stock equivalents at an effective price below the then exercise price. The Series J Warrants also provide for other standard adjustments upon the happening of certain customary events.",
            "type": "paragraph"
        },
        {
            "id": 89,
            "context": "The fair value of the Series J Warrants was calculated using a Black-Scholes model. The following assumptions were used in the Black-Scholes model to calculate the fair value of the Series J Warrants:\nSCHEDULE OF FAIR VALUE OF WARRANTS ISSUED\n\n| December 31, 2023 | March 31, 2023 |\n| Fair value of the Company\u2019s Common Stock | $ | 0.1393 | $ | 0.0290 |\n| Volatility | 73.50 | % | 74.37 | % |\n| Initial exercise price | $ | 0.1521 | $ | 0.1521 |\n| Warrant term (in years) | 3.3 | 4.1 |\n| Risk free rate | 4.01 | % | 3.55 | % |",
            "type": "table"
        },
        {
            "id": 90,
            "context": "The changes in warrants (Level 3 financial instruments) measured at fair value on a recurring basis for the nine months ended December 31, 2023 were as follows:\nSCHEDULE OF CHANGES IN WARRANTS MEASURED AT FAIR VALUE ON A RECURRING BASIS\n\n| Balance at March 31, 2023 | $ | 521,711 |\n| Change in fair value of derivative financial instruments - warrants | 5,075,489 |\n| Balance at December 31, 2023 | $ | 5,597,200 |",
            "type": "table"
        },
        {
            "id": 91,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 12. SHAREHOLDERS\u2019 EQUITY\nLincoln Park Capital Transaction - July 8, 2020 Purchase Agreement On July 8, 2020, the Company entered into a purchase agreement (the \u201c2020 LPC Purchase Agreement\u201d), and a registration rights agreement, with Lincoln Park Capital Fund, LLC (\u201cLincoln Park\u201d), pursuant to which Lincoln Park has committed to purchase up to $ 25.0 million of the Company\u2019s Common Stock, $ 0.001 par value per share, from time to time over the term of the 2020 LPC Purchase Agreement, at the Company\u2019s direction.",
            "type": "paragraph"
        },
        {
            "id": 92,
            "context": "The Company did not issue any shares of its Common Stock pursuant to the 2020 LPC Purchase Agreement during the three and nine months ended December 31, 2023 and 2022. In addition, there were no shares issued to Lincoln Park as additional commitment shares, pursuant to the 2020 LPC Purchase Agreement. The 2020 LPC Purchase Agreement expired on August 1, 2023.",
            "type": "paragraph"
        },
        {
            "id": 93,
            "context": "Summary of Common Stock Activity On November 22, 2023, the Company issued 1,642,971 shares of Common Stock in payment of director fees to be paid via the issuance of common stock, with such shares having an aggregate value on the date of original accrual of $ 60,000 and which were owed for periods prior to the current fiscal year and accrued as of the date of share issuance. The price of the Company\u2019s Common Stock on November 22, 2023, was $ 0.1533 per share. The aggregate value of the shares on the date of their issuance was $ 251,867 .",
            "type": "paragraph"
        },
        {
            "id": 94,
            "context": "On December 29, 2023, the Company issued 2,223,147 shares of Common Stock in payment of consultant fees to be paid via the issuance of common stock, with such shares having an aggregate value on the date of original accrual of $ 153,333 and which were owed for periods prior to the current fiscal year and accrued as of the date of share issuance. The price of the Company\u2019s Common Stock on December 29, 2023, was $ 0.14 per share. The aggregate value of the shares on the date of their issuance was $ 311,238 .",
            "type": "paragraph"
        },
        {
            "id": 95,
            "context": "As of December 31, 2023, there were 1,017,881,199 shares of Common Stock issued and 1,017,781,199 shares of Common Stock outstanding.\nNOTE 13. STOCK-BASED COMPENSATION\nPart of the compensation paid by the Company to its Directors and employees consists of the issuance of Common Stock or via the granting of options to purchase Common Stock.\nStock-based Director Compensation The Company\u2019s Director compensation policy, instituted in October 2009 and further revised in January 2016, includes provisions that a portion of director\u2019s fees are to be paid via the issuance of shares of the Company\u2019s Common Stock, in lieu of cash, with the valuation of such shares being calculated on quarterly basis and equal to the average closing price of the Company\u2019s Common Stock.",
            "type": "paragraph"
        },
        {
            "id": 96,
            "context": "During the nine months ended December 31, 2023, the Company accrued director\u2019s fees totaling $ 22,500 , which will be paid via cash payments totaling $ 22,500 . All of the accrued shares of common stock related to the Director\u2019s compensation policy were paid out on December 29, 2023.",
            "type": "paragraph"
        },
        {
            "id": 97,
            "context": "SCHEDULE OF STOCK BASED COMPENSATION\n\n| Balance of common stock owed at April 1, 2023 | $ | 60,000 |\n| Awarded shares | \u2014 |\n| Change in fair value of stock-based liabilities | 191,867 |\n| Issuance of common stock on November 22, 2023 | ( 251,867 | ) |\n| Balance of common stock owed at December 31, 2023 | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 98,
            "context": "Stock-based Employee/Consultant Compensation Employment contracts with the Company\u2019s President and Chief Executive Officer and certain other employees and engagement contracts with certain consultants include provisions for a portion of each employee\u2019s salaries or consultant\u2019s fees to be paid via the issuance of shares of the Company\u2019s Common Stock, in lieu of cash, with the valuation of such shares being calculated on a quarterly basis and equal to the average closing price of the Company\u2019s Common Stock.",
            "type": "paragraph"
        },
        {
            "id": 99,
            "context": "SCHEDULE OF STOCK BASED COMPENSATION\n\n| Balance of common stock owed at April 1, 2023 | $ | 4,278,333 |\n| Awarded shares | \u2014 |\n| Change in fair value of stock-based liabilities | 4,729,509 |\n| Common stock issued | ( 311,238 | ) |\n| Settlement of non-cash liability | ( 1,761,792 | ) |\n| Balance of common stock owed at December 31, 2023 | $ | 6,934,812 |",
            "type": "table"
        },
        {
            "id": 100,
            "context": "During the nine months ended December 31, 2023, the Company accrued no additional salaries owed to the Company\u2019s President, Chief Executive Officer and certain other employees which will be paid via the issuance of shares of Common Stock. As of December 31, 2023, the total obligation of $ 6,934,812 is outstanding which is recorded at fair value and is included in Accrued Expenses on the Condensed Consolidated Balance Sheets.",
            "type": "paragraph"
        },
        {
            "id": 101,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED) On November 6, 2023, the Company entered into a Settlement Agreement with a former executive who was terminated on February 7, 2022. The employment agreement with the former executive included annual compensation of $ 250,000 which was to be paid via the issuance of shares of Common Stock. At the date of the former executive\u2019s termination an aggregate of 14,892,580 shares of Common Stock (the \u201cDeferred Shares\u201d) were due to the former executive, with such number of shares representing an aggregate of $ 1,000,000 in compensation earned pursuant to the relevant employment agreement at an annual rate of $ 250,000 . Pursuant to the Settlement Agreement, the former executive irrevocably elected to relinquish all rights and claims to the Deferred Shares. The Company is released of any obligation to issue the Deferred Shares and further acknowledges that no Deferred Shares will be issued to or received by the former employee. The price of the Company\u2019s Common Stock on November 6, 2023 was $ 0.1183 per share and the value of the Deferred Shares on this date was $ 1,761,792 . The Company recorded other income from gain on settlement agreement for this amount on the unaudited Condensed Consolidated Statements of Operations.",
            "type": "paragraph"
        },
        {
            "id": 102,
            "context": "On December 29, 2023, the Company issued 2,223,147 shares of Common Stock in satisfaction of accrued consultant fees.\nOptions Under its 2014 Stock Option Plan and prior options plans, the Company may grant stock options to officers, selected employees, as well as members of the Board of Directors and advisory board members. All options have generally been granted at a price equal to or greater than the fair market value of the Company\u2019s Common Stock at the date of the grant. Generally, options are granted with a vesting period of up to three years and expire ten years from the date of grant.",
            "type": "paragraph"
        },
        {
            "id": 103,
            "context": "The fair value of option awards is estimated on the date of grant using the Black-Scholes option-pricing model. The exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company\u2019s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The expected term of the Company\u2019s stock options for employees has been determined utilizing the \u201csimplified\u201d method for awards, since the Company does not have sufficient exercise history to estimate term of its historical option awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.",
            "type": "paragraph"
        },
        {
            "id": 104,
            "context": "The grant date fair value of option awards is determined using the Black Scholes option-pricing model. The following assumptions were used for the nine months ended December 31, 2023 and year ended March 31, 2023:\nSCHEDULE OF GRANT DATE FAIR VALUE OF OPTION AWARDS\n\n| December 31, 2023 | March 31, 2023 |\n| Term (in years) | 10 | 10 |\n| Exercise Price | $ 0.08 -$ 0.09 | $ 0.03 -$ 0.04 |\n| Dividend Yield | \u2014 | \u2014 |\n| Expected Volatility | 80 %- 81 | % | 79 %- 80 | % |\n| Risk Free Rate | 4.27 %- 4.69 | % | 2.99 %- 4.01 | % |",
            "type": "table"
        },
        {
            "id": 105,
            "context": "A summary of the activity of Company\u2019s 2014 Stock Option Plan for the nine months ended December 31, 2023 is as follows:\nSCHEDULE OF STOCK OPTION PLAN\n\n| Shares | Weighted | Weighted Average Remaining Contractual | Aggregate |\n| Underlying Options | Average Exercise Price | Term (in years) | Intrinsic Value |\n| Outstanding at March 31, 2023 | 15,370,000 | $ | 0.07 | 7.4 | $ | \u2014 |\n| Granted | 4,100,000 | $ | 0.09 | 10.0 | $ | \u2014 |\n| Expired and Forfeited | ( 3,840,000 | ) | $ | 0.07 | 1.8 | $ | \u2014 |\n| Outstanding at December 31, 2023 | 15,630,000 | $ | 0.05 | 9.0 | $ | 1,429,822 |\n| Exercisable at December 31, 2023 | 343,334 | $ | 0.19 | 4.6 | $ | 6,850 |",
            "type": "table"
        },
        {
            "id": 106,
            "context": "The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company\u2019s Common Stock as of December 31, 2023 of $ 0.14 for those awards with strike prices lower than the quoted price of the Company\u2019s Common Stock as of December 31, 2023. As of December 31, 2023, there was $ 450,470 in unrecognized stock based compensation expense that will be recognized over a weighted average 2.37 year period.",
            "type": "paragraph"
        },
        {
            "id": 107,
            "context": "On September 5, 2023, options were granted to the Chief Financial Officer pursuant to the 2014 Plan to purchase an aggregate of 3,000,000 shares of Common Stock. The options have an exercise price of $ 0.0898 per share, the fair market value of the Common Stock on the date of grant. The options granted will vest one third for each of the next three years upon the anniversary date of the grant and have a ten-year expiration date.",
            "type": "paragraph"
        },
        {
            "id": 108,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED) On September 19, 2023, options were granted to one employee pursuant to the 2014 Plan to purchase an aggregate of 1,000,000 shares of Common Stock. The options have an exercise price of $ 0.0819 per share, the fair market value of the Common Stock on the date of grant. The options granted will vest one third for each of the next three years upon the anniversary date of the grant and have a ten-year expiration date.",
            "type": "paragraph"
        },
        {
            "id": 109,
            "context": "On October 2, 2023, options were granted to one employee pursuant to the 2014 Plan to purchase an aggregate of 100,000 shares of Common Stock. The options have an exercise price of $ 0.0938 per share, the fair market value of the Common Stock on the date of grant. The options granted will vest one third for each of the next three years upon the anniversary date of the grant and have a ten-year expiration date.",
            "type": "paragraph"
        },
        {
            "id": 110,
            "context": "The weighted-average grant-date fair value of stock options granted during the nine months ended December 31, 2023 under the 2014 Plan was $ 0.0754 .\nNOTE 14. CONCENTRATIONS AND CREDIT RISK\nRevenues\nTwo customers accounted for approximately 57 % of the Company\u2019s revenues for the nine months ended December 31, 2023. These three customers accounted for approximately 30 %, and 27 %, of revenues each, respectively.\nTwo customers accounted for approximately 96 % of the Company\u2019s revenues for the nine months ended December 31, 2022. These two customers accounted for approximately 85 % and 11 % of revenue each, respectively.\nAccounts Receivable\nTwo customers accounted for approximately 77 % of the Company\u2019s accounts receivable as of December 31, 2023. These two customers accounted for approximately 45 % and 32 % of accounts receivable each, respectively.\nOne customer accounted for approximately 89 % of the Company\u2019s accounts receivable as of December 31, 2022.\nPurchasing Two suppliers accounted for approximately 43 % of the Company\u2019s purchases of raw materials for the nine months ended December 31, 2023. These two customers accounted for approximately 30 %, and 13 %, of purchasing each, respectively.",
            "type": "paragraph"
        },
        {
            "id": 111,
            "context": "One supplier accounted for approximately 62 % of the Company\u2019s purchases of raw materials for the nine months ended December 31, 2022.\nNOTE 15. SEGMENT RESULTS FASB ASC 280-10-50 requires use of the \u201cmanagement approach\u201d model for segment reporting. The management approach is based on the way a company\u2019s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.",
            "type": "paragraph"
        },
        {
            "id": 112,
            "context": "The Company has determined that its reportable segments are ANDAs for generic products and NDAs for branded products. The Company identified its reporting segments based on the marketing authorization relating to each and the financial information used by its chief operating decision maker to make decisions regarding the allocation of resources to and the financial performance of the reporting segments.",
            "type": "paragraph"
        },
        {
            "id": 113,
            "context": "Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company\u2019s unaudited condensed consolidated financial statements.\n\nELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nThe following represents selected information for the Company\u2019s reportable segments:\nSCHEDULE OF SELECTED INFORMATION FOR REPORTABLE SEGMENTS\n\n| 2023 | 2022 | 2023 | 2022 |\n| For the Three Months Ended December 31, | For the Nine Months Ended December 31, |\n| 2023 | 2022 | 2023 | 2022 |\n| Operating Income by Segment |\n| ANDA | $ | 5,637,283 | $ | 3,828,493 | $ | 13,073,023 | $ | 7,947,118 |\n| Operating income by Segment | $ | 5,637,283 | $ | 3,828,493 | $ | 13,073,023 | $ | 7,947,118 |",
            "type": "table"
        },
        {
            "id": 114,
            "context": "The Company notes that there was no revenue related to the NDA segment for the three and nine months ended December 31, 2023 and 2022.\nThe table below reconciles the Company\u2019s operating income by segment to income before income taxes as reported in the Company\u2019s unaudited condensed consolidated statements of operations:\nSCHEDULE OF OPERATING INCOME BY SEGMENT TO INCOME FROM OPERATIONS\n\n| 2023 | 2022 | 2023 | 2022 |\n| For the Three Months Ended December 31, | For the Nine Months Ended December 31, |\n| 2023 | 2022 | 2023 | 2022 |\n| Operating income by segment | $ | 5,637,283 | $ | 3,828,493 | $ | 13,073,023 | $ | 7,947,118 |\n| Corporate unallocated costs | ( 1,711,275 | ) | ( 378,867 | ) | ( 4,906,187 | ) | ( 1,465,792 | ) |\n| Interest income | 5,249 | 15 | 16,085 | 187 |\n| Interest expense and amortization of debt issuance costs | ( 121,628 | ) | ( 322,681 | ) | ( 371,478 | ) | ( 782,221 | ) |\n| Depreciation and amortization expense | ( 343,537 | ) | ( 317,685 | ) | ( 999,059 | ) | ( 933,531 | ) |\n| Significant non-cash items | 1,711,977 | ( 172,841 | ) | 1,654,200 | ( 484,894 | ) |\n| Change in fair value of derivative instruments | ( 2,417,772 | ) | 372,894 | ( 5,075,489 | ) | 561,070 |\n| Change in fair value of stock-based liabilities | ( 2,854,556 | ) | \u2014 | ( 4,921,376 | ) | \u2014 |\n| Income(Loss) before income taxes | $ | ( 94,259 | ) | $ | 3,009,328 | $ | ( 1,530,281 | ) | $ | 4,841,937 |",
            "type": "table"
        },
        {
            "id": 115,
            "context": "NOTE 16. RELATED PARTY AGREEMENTS\nMikah Pharma, LLC Agreements In May 2020, Praxgen (formerly known as SunGen Pharma LLC), pursuant to an asset purchase agreement, assigned its rights and obligations under the Praxgen Agreement for Amphetamine IR and Amphetamine ER to Mikah Pharma LLC (\u201cMikah\u201d). The ANDAs for Amphetamine IR and Amphetamine ER are now registered under Elite\u2019s name. Mikah will now be Elite\u2019s partner with respect to Amphetamine IR and ER and will assume all the rights and obligations for these products from Praxgen. Mikah was founded in 2009 by Nasrat Hakim, a related party and the Company\u2019s President, Chief Executive Officer and Chairman of the Board.",
            "type": "paragraph"
        },
        {
            "id": 116,
            "context": "In June 2021, the Company entered into a development and license agreement with Mikah, pursuant to which Mikah will engage in the research, development, sales and licensing of generic pharmaceutical products. In addition, Mikah will collaborate to develop and commercialize generic products including formulation development, analytical method development, manufacturing, sales and marketing of generic products. Initially two generic products were identified for the parties to develop.",
            "type": "paragraph"
        },
        {
            "id": 117,
            "context": "As of December 31, 2023, the Company owes an aggregate of $ 3,389,949 to Mikah in accordance with the agreements, with such amount being recorded as an accrued expense on the unaudited condensed consolidated balance sheets.",
            "type": "paragraph"
        },
        {
            "id": 118,
            "context": "Consultants Agreements Employment contracts with certain consultants include provisions for a portion of the consultant\u2019s fees to be paid via the issuance of shares of the Company\u2019s Common Stock, in lieu of cash, with the valuation of such shares being calculated on a quarterly basis and equal to the average closing price of the Company\u2019s Common Stock. On December 29, 2023, the Company issued 2,223,147 shares of Common Stock in satisfaction of accrued consultant fees owed to one consultant.",
            "type": "paragraph"
        },
        {
            "id": 119,
            "context": "ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nNOTE 17. INCOME TAXES\nThe Company\u2019s income tax benefit was $ 18.3 million and income tax expense was $ 0.05 million for the nine months ended December 31, 2023 and 2022, respectively.\nThe Company\u2019s income tax benefit was $ 0.8 million and income tax expense was $ 0.04 million for the three months ended December 31, 2023 and 2022, respectively. During the nine months ended December 31, 2023, the Company recorded a discrete tax benefit of $ 18.1 million related to the Company\u2019s release of the valuation allowance against deferred tax assets related to U.S. federal net operating losses carryforwards and research and development tax credits, which are expected to be realized based on demonstrated current profitability and its expectations of forecasted income. For the nine months ended December 31, 2023, the release in the valuation allowance is the primary reason that the effective tax rate is different than the United States federal statutory rate of 21 %.",
            "type": "paragraph"
        },
        {
            "id": 120,
            "context": "NOTE 18. SUBSEQUENT EVENTS\nThe Company has evaluated subsequent events from the balance sheet date through February 14, 2024, and note the following subsequent events:\n140 Ludlow Office Lease The Company entered into a five-year office lease agreement for a portion of a one-story warehouse, located at 140 Ludlow Avenue, Northvale, New Jersey (the 140 Ludlow Ave. lease\u201d) which began on January 22, 2024 and ends on December 31, 2028.",
            "type": "paragraph"
        },
        {
            "id": 121,
            "context": "The following discussion of our financial condition and results of operations for the Nine Months Ended December 31, 2023 and 2022 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended March 31, 2023. We use words such as \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201ccontinuing,\u201d \u201congoing,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d and similar expressions to identify forward-looking statements.",
            "type": "paragraph"
        },
        {
            "id": 122,
            "context": "Unless expressly indicated or the context requires otherwise, the terms \u201cElite\u201d, the \u201cCompany\u201d, \u201cwe\u201d, \u201cus\u201d, and \u201cour\u201d refer to Elite Pharmaceuticals, Inc. and subsidiary.\nBackground Elite Pharmaceuticals, Inc., a Nevada corporation (the \u201cCompany\u201d, \u201cElite\u201d, \u201cElite Pharmaceuticals\u201d, the \u201cregistrant\u201d, \u201cwe\u201d, \u201cus\u201d or \u201cour\u201d) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (\u201cElite Labs\u201d), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.",
            "type": "paragraph"
        },
        {
            "id": 123,
            "context": "We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology for the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry.",
            "type": "paragraph"
        },
        {
            "id": 124,
            "context": "We occupy manufacturing, warehouse, laboratory and office space at 165 Ludlow Avenue and 135 Ludlow Avenue in Northvale, NJ (the \u201cNorthvale Facility\u201d). The Northvale Facility operates under Current Good Manufacturing Practice and is a United States Drug Enforcement Agency registered facility for research, development and manufacturing. We are also party to an operating lease for office space at Pompano Beach, Florida (the \u201cPompano Office Lease\u201d).",
            "type": "paragraph"
        },
        {
            "id": 125,
            "context": "Strategy We focus our efforts on the following areas: (i) manufacturing of a line of generic pharmaceutical products with approved Abbreviated New Drug Applications (\u201cANDAs\u201d); (ii) development of additional generic pharmaceutical products; (iii) development of the other product candidates in our pipeline including the products with our partners; (iv) commercial exploitation of our products either by sales under our own label, by license and the collection of royalties, or through the manufacture of our formulations; and (v) development of new products and the expansion of our licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations.",
            "type": "paragraph"
        },
        {
            "id": 126,
            "context": "Our focus is on the development of various types of drug products, including generic drug products which require ANDAs as well as branded drug products which require New Drug Applications (\u201cNDAs\u201d) under Section 505(b)(1) or 505(b)(2) of the Drug Price Competition and Patent Term Restoration Act of 1984.",
            "type": "paragraph"
        },
        {
            "id": 127,
            "context": "We believe that our business strategy enables us to reduce its risk by having a diverse product portfolio that includes generic products in various therapeutic categories and to build collaborations and establish licensing agreements with companies with greater resources thereby allowing us to share costs of development and improve cash-flow.",
            "type": "paragraph"
        },
        {
            "id": 128,
            "context": "Commercial Products\nWe own, license, contract manufacture or have contractual rights to receive royalties from the following products currently approved for commercial sale:\n\n| Product | Branded Product Equivalent | Therapeutic Category | Launch Date |\n| Phentermine HCl 37.5mg tablets | Adipex-P\u00ae | Bariatric | April 2011 |\n| Phendimetrazine Tartrate 35mg tablets | Bontril\u00ae | Bariatric | November 2012 |\n| Phentermine HCl 15mg and 30mg capsules | Adipex-P\u00ae | Bariatric | April 2013 |\n| Naltrexone HCl 50mg tablets | Revia\u00ae | Addiction Treatment | September 2013 |\n| Isradipine 2.5mg and 5mg capsules | N/A | Cardiovascular | January 2015 |\n| Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules | Surmontil\u00ae | Antidepressant | May 2017 |\n| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets | Adderall\u00ae | Central Nervous System Stimulant | April 2019 |\n| Dantrolene Sodium Capsules 25mg, 50mg and 100mg | Dantrium\u00ae | Muscle Relaxant | June 2019 |\n| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules | Adderall XR\u00ae | Central Nervous System Stimulant | March 2020 |\n| Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules | Loxapine\u00ae | Antipsychotic | May 2021 |",
            "type": "table"
        },
        {
            "id": 129,
            "context": "Products Under FDA Review\nSequestOx\u2122 - Immediate Release Oxycodone with sequestered Naltrexone SequestOx\u2122 is our abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. SequestOx\u2122 is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone which incorporates 5mg, 10mg, 15mg, 20mg and 30mg doses of oxycodone into capsules.",
            "type": "paragraph"
        },
        {
            "id": 130,
            "context": "In January 2016, the Company submitted a 505(b)(2) New Drug Application for SequestOx\u2122, after receiving a waiver of the $2.3 million filing fee from the FDA. In March 2016, the Company received notification of the FDA\u2019s acceptance of this filing and that such filing has been granted priority review by the FDA with a target action under the Prescription Drug User Fee Act of July 14, 2016.",
            "type": "paragraph"
        },
        {
            "id": 131,
            "context": "On July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx\u2122 NDA is complete and the application is not ready for approval in its present form.",
            "type": "paragraph"
        },
        {
            "id": 132,
            "context": "On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for or SequestOx\u2122. The mean Tmax (the amount of time that a drug is present at the maximum concentration in serum) of SequestOx\u2122 was 4.6 hr. with a range of 0.5 hr. to 12 hr. and the mean Tmax of the comparator, Roxicodone\u00ae, was 3.4 hr. with a range of 0.5 hr. to 12 hr. A key objective for the study was to determine if the reformulated SequestOx\u2122 had a similar Tmax to the comparator when taken with a high fat meal. Based on these results, the Company paused clinical trials for this formulation of SequestOx\u2122. On January 30, 2018, the Company reported positive topline results from a pilot study conducted for a modified SequestOx\u2122 wherein, based on the results of this pilot study, the modified SequestOx\u2122 formulation is expected to achieve bioequivalence with a Tmax range equivalent to the reference product when conducted in a pivotal trial under fed conditions. The Company has provided the pilot data to the FDA, requesting clarification as to the requirements for resubmission of the NDA. The FDA has provided guidance for repeated bio-equivalence studies in order to bridge the new formulation to the original SequestOx\u2122 studies and also extended our filing fee waiver until July 2023. Due to the prohibitive cost of such repeated bio-equivalence studies and the uncertain commercial viability given the regulatory and competitive landscape, the Company has paused development of this product candidate.",
            "type": "paragraph"
        },
        {
            "id": 133,
            "context": "There can be no assurances of the Company conducting future clinical trials, or if such trials are conducted, there can be no assurances of the success of any future clinical trials, or if such trials are successful, there can be no assurances that an intended future resubmission of the NDA product filing, if made, will be accepted by or receive marketing approval from the FDA. In addition, even if marketing authorization is received, there can be no assurances that there will be future revenues or profits, or that any such future revenues or profits would be in amounts that provide adequate return on the significant investments made to secure this marketing authorization.",
            "type": "paragraph"
        },
        {
            "id": 134,
            "context": "Generic Products Filed Currently the Company has filed a generic antimetabolite ANDA and a generic dopamine agonist ANDA and these products are under review by the FDA. On August 17, 2023, the Company also submitted an ANDA for an opiate analgesic for pain management and it was accepted for review by FDA on September 19, 2023. On December 21, 2023, the FDA accepted for review an ANDA for an undisclosed generic drug product in a class of medications known as central nervous stimulants.",
            "type": "paragraph"
        },
        {
            "id": 135,
            "context": "Approved Products Not Yet Commercialized\nAcetaminophen and Codeine Phosphate The Company received approval on September 10, 2019 from the FDA of an ANDA for a generic version of Tylenol\u00ae with Codeine (acetaminophen and codeine phosphate) 300mg/7.5mg, 300mg/15mg, 300mg/30mg and 300mg/60mg tablets. Acetaminophen with codeine is a combination medication indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Acetaminophen with codeine products have annual U.S. sales of approximately $45 million according to IQVIA (formerly QuintilesIMS Health Data). The Company is not pursuing licensing deals for any opioids at this time until the market changes. The Company will wait for the market to stabilize before pursuing these opportunities.",
            "type": "paragraph"
        },
        {
            "id": 136,
            "context": "Doxycycline Hyclate Tablets The Company received approval in April 2022 from the FDA of an ANDA for a generic version of an antibiotic product. According to QVIA (formerly QuintilesIMS Health) data, the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $85 million for the twelve months ending September 30, 2019. The product is jointly owned by Elite and Praxgen Pharmaceuticals LLC, formerly SunGen Pharma LLC, (\u201cPraxgen\u201d).",
            "type": "paragraph"
        },
        {
            "id": 137,
            "context": "There can be no assurances in relation to any of the above approved products not yet commercialized, that there will be future revenues of profits, or that any such future revenues or profits would be in amounts that provide adequate return on the significant investments made to secure these marketing authorizations.",
            "type": "paragraph"
        },
        {
            "id": 138,
            "context": "Critical Accounting Policies and Estimates The preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with GAAP, and our discussion and analysis of the Company\u2019s financial condition and operating results require our management to make judgments, assumptions and estimates that affect the amounts reported in the Company\u2019s unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates and such differences may be material. We have identified below the critical accounting policies, which are assumptions made by management about matters that are highly uncertain and that are of critical importance in the presentation of our financial position, results of operations and cash flows. Due to the need to make estimates about the effect of matters that are inherently uncertain, materially different amounts could be reported under different conditions or using different assumptions. On a regular basis, we review our critical accounting policies and how they are applied in the preparation our financial statements.",
            "type": "paragraph"
        },
        {
            "id": 139,
            "context": "Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.",
            "type": "paragraph"
        },
        {
            "id": 140,
            "context": "Revenue Recognition - The Company generates revenue from manufacturing and licensing fees and sales of generic pharmaceuticals bearing the Elite label to pharmaceutical distributors for pharmacies and institutions. Manufacturing fees include the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, through the manufacture of formulations and the development of new products. Revenues earned from the sale of Elite label products are recorded at their net realizable value which consists of gross amounts invoiced reduced by contractual reductions, including, without limitation, chargebacks, discounts and program rebates, as applicable. Licensing fees include the commercialization of products either by license and the collection of royalties, or the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations.",
            "type": "paragraph"
        },
        {
            "id": 141,
            "context": "Under ASC 606, Revenue from Contacts with Customers (\u201cASC 606\u201d), the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.",
            "type": "paragraph"
        },
        {
            "id": 142,
            "context": "Nature of goods and services\nThe following is a description of the Company\u2019s goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable:\na) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if, and when, the products are approved. These products include products using controlled-release drug technology. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release pharmaceutical products.",
            "type": "paragraph"
        },
        {
            "id": 143,
            "context": "The Company recognizes revenue when the customer obtains control of the Company\u2019s product based on the contractual shipping terms of the contract, at which time the performance obligation is deemed to be completed. The Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer.",
            "type": "paragraph"
        },
        {
            "id": 144,
            "context": "b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales.",
            "type": "paragraph"
        },
        {
            "id": 145,
            "context": "If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.",
            "type": "paragraph"
        },
        {
            "id": 146,
            "context": "The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will recognize revenue from the milestone when there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.",
            "type": "paragraph"
        },
        {
            "id": 147,
            "context": "Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.",
            "type": "paragraph"
        },
        {
            "id": 148,
            "context": "When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company\u2019s contracts contained a significant financing component as of December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 149,
            "context": "In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer\u2019s products occurs.\nc) Sale of product under the Elite label The Company began direct sales of products under the Company\u2019s own label on April 1, 2023. License agreements will remain in place for select products. With this transition, however, a large portion of the manufacturing and license fees now reported will be replaced with revenues from sales of Elite labeled pharmaceutical products to distributors for pharmacies and institutions.",
            "type": "paragraph"
        },
        {
            "id": 150,
            "context": "The Company recognizes revenue when the customer obtains control of the Company\u2019s product based on the contractual shipping terms, at which time the performance obligation is deemed to be completed. The Company is primarily responsible for fulfilling the promise to deliver the product and bears risk of loss while the inventory is in-transit to the purchaser. Revenue is measured as the amount of consideration earned from the sale of Elite labeled pharmaceutical products are recorded at their net realizable value which consists of gross amounts invoiced reduced by contractual reductions, including, without limitation, chargebacks, discounts and program rebates, as applicable.",
            "type": "paragraph"
        },
        {
            "id": 151,
            "context": "Accounts Receivable and Allowance for Expected Credit Losses - Accounts receivable are comprised of balances due from customers, net of estimated allowances for expected credit losses, and other contractual deductions, including, without limitation, chargebacks, discounts and program rebates. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances.",
            "type": "paragraph"
        },
        {
            "id": 152,
            "context": "The allowance for expected credit losses is based on the probability of future collection under the current expected credited loss (\u201cCECL\u201d) impairment model under Accounting Standards Update (\u201cASU\u201d) 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Assets, which was adopted by the Company on April 1, 2023, as discussed below within Recently Adopted Accounting Pronouncements. Under the CECL impairment model, the Company determines its allowance by applying a loss-rate method based on an aging schedule using the Company\u2019s historical loss rate. The Company also considers reasonable and supportable current information in determining its estimated loss rates, such as external forecasts, macroeconomic trends or other factors including customers\u2019 credit risk and historical loss experience. The adequacy of the allowance is evaluated on a regular basis. Account balances are written off after all means of collection are exhausted and the balance is deemed uncollectible. Subsequent recoveries are credited to the allowance. Changes in the allowance are recorded as adjustments to credit losses in the period incurred.",
            "type": "paragraph"
        },
        {
            "id": 153,
            "context": "Prior to April 1, 2023, trade receivables were presented net of allowance for expected credit losses based on the credit risk of specific clients, past collection history, and management\u2019s evaluation of other risks. Expected credit losses stemming from unbilled receivables expected to be billed between March 31, 2024 and March 31, 2028 include additional risk premiums estimated based on factors such as projected inflation, projected decreases in GDP, and projected unemployment.",
            "type": "paragraph"
        },
        {
            "id": 154,
            "context": "Income Taxes - Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future.",
            "type": "paragraph"
        },
        {
            "id": 155,
            "context": "The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.",
            "type": "paragraph"
        },
        {
            "id": 156,
            "context": "The Company operates in multiple tax jurisdictions within the United States of America. The Company remains subject to examination in all tax jurisdiction until the applicable statutes of limitation expire. As of December\u202f31, 2023, a summary of the tax years that remain subject to examination in our major tax jurisdictions are: United States \u2013 Federal, 2016 and forward. The Company did not record unrecognized tax positions for the nine months ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 157,
            "context": "New Accounting Pronouncements For a description of recent accounting standards, including the expected dates of adoption and estimated effects, if any, on our financial statements, see \u201cNote 1. Summary of Significant Accounting Polices: Recently Issued Accounting Pronouncements\u201d in Part II, Item 1 of this Form 10-Q.",
            "type": "paragraph"
        },
        {
            "id": 158,
            "context": "Results of Operations\nThe following set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not necessarily indicative of future results.\nThree months ended December 31, 2023 compared to the three months ended December 31, 2022\nRevenue, Cost of revenue and Gross profit:\n\n| For the Three Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Manufacturing fees | $ | 14,791,110 | $ | 7,798,159 | $ | 6,992,951 | 90 | % |\n| Licensing fees | 747,690 | 1,451,907 | (704,217 | ) | (49 | )% |\n| Total revenue | 15,538,800 | 9,250,066 | 6,288,734 | 68 | % |\n| Cost of manufacturing | 8,497,727 | 4,330,841 | 4,166,886 | 96 | % |\n| Gross profit | $ | 7,041,073 | $ | 4,919,225 | $ | 2,121,848 | 43 | % |\n| Gross profit - percentage | 45 | % | 53 | % |",
            "type": "table"
        },
        {
            "id": 159,
            "context": "Total revenues for the three months ended December 31, 2023 increased by $6.3 million or 68%, to $15.5 million, as compared to $9.3 million, for the corresponding period of the prior year, primarily due to the launch of the Elite label during the current fiscal year which achieved increased sales for the quarter ended December 31, 2023, as compared to the comparable quarter of the prior year, which did not include any sales of Elite label products.",
            "type": "paragraph"
        },
        {
            "id": 160,
            "context": "Manufacturing fees revenue increased by $7.0 million, or 90%, primarily due to the launch of the Elite label during the current fiscal year which achieved increased sales for the quarter ended December 31, 2023, as compared to the comparable quarter of the prior year, which did not include any sales of Elite label products.",
            "type": "paragraph"
        },
        {
            "id": 161,
            "context": "Licensing fees revenue decreased by $0.7 million, or 49%. This decrease is primarily due to the expiration of the marketing alliance agreements between the Company and Lannett Company, Inc. dated March 6, 2019 and April 9, 2019 (the \u201cLannett Agreements\u201d) on March 31, 2023. The revenue streams that were generated during periods ending on or prior to March 31, 2023 and attributed to the Lannett Agreements, included profit splits on the sale by Lannett of Amphetamine IR and Amphetamine ER. Since April 1, 2023, these products are now sold by the Company under its own label, with revenues being recorded as manufacturing revenues instead of licensing fees going forward.",
            "type": "paragraph"
        },
        {
            "id": 162,
            "context": "Cost of revenue consists of manufacturing and assembly costs. Our cost of revenue increased by $4.2 million or 96%, to $8.5 million as compared to $4.3 million for the corresponding period in the prior fiscal year. This increase was due to an increased volume of products sold during the three months ended December 31, 2023, as compared to the comparable period of the prior fiscal year, as noted above.",
            "type": "paragraph"
        },
        {
            "id": 163,
            "context": "Our gross profit margin was 45% during the three months ended December 31, 2023 as compared to 53% during the comparable period of the prior fiscal year. The decrease is due to total revenues consisting of a greater proportion of manufacturing revenues, as compared to the comparable period of the prior year, with the associated increase in costs of manufacturing resulting in lower gross profit margins as compared to the comparable period of the prior year which included a greater proportion of license fees that does not have a cost of manufacturing.",
            "type": "paragraph"
        },
        {
            "id": 164,
            "context": "Operating expenses:\n\n| For the Three Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Operating expenses: |\n| Research and development | $ | 1,403,790 | $ | 1,443,361 | $ | (39,571 | ) | (3 | )% |\n| General and administrative | 1,711,275 | 1,186,049 | 525,226 | 44 | % |\n| Non-cash compensation | 49,815 | 13,030 | 36,785 | 282 | % |\n| Depreciation and amortization | 343,537 | 317,685 | 25,852 | 8 | % |\n| Total operating expenses | $ | 3,508,417 | $ | 2,960,125 | $ | 548,292 | 19 | % |",
            "type": "table"
        },
        {
            "id": 165,
            "context": "Operating expenses consist of research and development costs, general and administrative costs, non-cash compensation and depreciation and amortization expenses. Operating expenses for the three months ended December 31, 2023 increased by $0.5 million, or 19%, to $3.5 million as compared to $3.0 million for the corresponding period in the prior fiscal year, largely due to an increase in general and administrative costs of $0.5 million.",
            "type": "paragraph"
        },
        {
            "id": 166,
            "context": "Research and development costs during the three months ended December 31, 2023 were $1.4 million, a decrease of less than $0.1 million, or 3%, from approximately $1.4 million of such costs for the comparable period of the prior year.",
            "type": "paragraph"
        },
        {
            "id": 167,
            "context": "General and administrative expenses for the three months ended December 31, 2023 were $1.7 million, an increase of $0.5 million or approximately 44% from the comparable period of the prior fiscal year, largely due to an increased human resource headcount and costs as compared to the comparable period of the prior year.",
            "type": "paragraph"
        },
        {
            "id": 168,
            "context": "Non-cash compensation expense for the three months ended December 31, 2023 and 2022 was less than $0.1 million.\nDepreciation and amortization expenses from the three months ended December 31, 2023 were $0.3 million, which was virtually unchanged from $0.3 million in such costs for the comparable period of the prior fiscal year. As a result of the foregoing, our income from operations during the three months ended December 31, 2023 was $3.5 million, compared to income from operations of $2.0 million for the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 169,
            "context": "Other income (expense):\n\n| For the Three Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Other income (expense): |\n| Change in fair value of derivative financial instruments - warrants | $ | (2,417,772 | ) | $ | 372,894 | $ | (2,790,666 | ) | (748 | )% |\n| Change in fair value of stock-based liabilities | (2,854,556 | ) | \u2014 | (2,854,556 | ) | \u2014 | % |\n| Interest expense and amortization of debt issuance costs | (121,628 | ) | (322,681 | ) | 201,053 | (62 | )% |\n| Gain from settlement agreements | 1,761,792 | \u2014 | 1,761,792 | \u2014 | % |\n| Gain on sale of ANDA | \u2014 | 1,000,000 | (1,000,000 | ) | (100 | )% |\n| Interest income | 5,249 | 15 | 5,234 | 34,893 | % |\n| Other (expense) income, net | $ | (3,626,915 | ) | $ | 1,050,228 | $ | (4,677,143 | ) | (445 | )% |",
            "type": "table"
        },
        {
            "id": 170,
            "context": "Other income (expense) for the three months ended December 31, 2023 was an other expense of $3.6 million, a decrease of $4.7 million from an other income of $1.1 million for the comparable period of the prior fiscal year. The decrease was primarily due to net increases of other expenses of $2.9 million relating to the change in fair value of stock-based liabilities and $2.8 million relating to the change in fair value of derivative financial instruments, a decrease in other income of $1.0 million from Gain on sale of ANDA that occurred in the prior year only, offset by a decrease in other expenses of $0.2 million relating to the decrease in interest expense and amortization of debt issuance costs in the current fiscal year as compared to the comparable period of the prior fiscal year. The change in the fair value of derivative instruments and stock-based liabilities is determined in large part by the change in the closing price of the Company\u2019s Common Stock as of the end of the period, as compared to the closing price at the beginning of the period, with a strong inverse relationship between the fair value of our derivatives instruments and stock-based liabilities and decreases in the closing price of the Company\u2019s Common Stock. The decrease in interest expense associated with the loans payable is due in large part to the Company paying off the principal balance of the EWB loan during the fiscal year ended March 31, 2023, resulting in no interest on the EWB loan incurred for the three months ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 171,
            "context": "As a result of the foregoing, our net loss before income taxes for the three months ended December 31, 2023 was $0.1 million, compared to net income before income taxes of $3.0 million for the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 172,
            "context": "Nine months ended December 31, 2023 compared to the nine months ended December 31, 2022\nRevenue, Cost of revenue and Gross profit:\n\n| For the Nine Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Manufacturing fees | $ | 36,208,217 | $ | 21,312,663 | $ | 14,895,554 | 70 | % |\n| Licensing fees | 2,467,844 | 4,200,888 | (1,733,044 | ) | (41 | )% |\n| Total revenue | 38,676,061 | 25,513,551 | 13,162,510 | 52 | % |\n| Cost of manufacturing | 20,437,354 | 12,360,935 | 8,076,419 | 65 | % |\n| Gross profit | $ | 18,238,707 | $ | 13,152,616 | $ | 5,086,091 | 39 | % |\n| Gross profit - percentage | 47 | % | 52 | % |",
            "type": "table"
        },
        {
            "id": 173,
            "context": "Total revenues for the nine months ended December 31, 2023 increased by $13.2 million or 52%, to $38.7 million, as compared to $25.5 million, for the corresponding period of the prior year, primarily due to the launch of the Elite label during the current fiscal year which achieved increased sales for the nine months ended December 31, 2023, as compared to the comparable quarter of the prior year, which did not include any sales of Elite label products.",
            "type": "paragraph"
        },
        {
            "id": 174,
            "context": "Manufacturing fees revenue increased by $14.9 million, or 70%, primarily due to the launch of the Elite label during the current fiscal year which achieved increased sales for the nine months ended December 31, 2023, as compared to the comparable quarter of the prior year, which did not include any sales of Elite label products.",
            "type": "paragraph"
        },
        {
            "id": 175,
            "context": "Licensing fees revenue decreased by $1.7 million, or 41%. This decrease is primarily due to the expiration of the marketing alliance agreements between the Company and Lannett Company, Inc. dated March 6, 2019 and April 9, 2019 (the \u201cLannett Agreements\u201d) on March 31, 2023. The revenue streams that were generated during periods ending on or prior to March 31, 2023 and attributed to the Lannett Agreements, included profit splits on the sale by Lannett of Amphetamine IR and Amphetamine ER. Since April 1, 2023, these products are now sold by the Company under its own label, with revenues being recorded as manufacturing revenues instead of licensing fees going forward.",
            "type": "paragraph"
        },
        {
            "id": 176,
            "context": "Cost of revenue consists of manufacturing and assembly costs. Our cost of revenue increased by $8.1 million or 65%, to $20.4 million as compared to $12.4 million for the corresponding period in the prior fiscal year. This increase was due to an increased volume of products sold during the nine months ended December 31, 2023, as compared to the comparable period of the prior fiscal year, as noted above.",
            "type": "paragraph"
        },
        {
            "id": 177,
            "context": "Our gross profit margin was 47% during the nine months ended December 31, 2023 as compared to 52% during the comparable period of the prior fiscal year. The decrease is due to total revenues consisting of a greater proportion of manufacturing revenues, as compared to the comparable period of the prior year, with the associated increase in costs of manufacturing resulting in lower gross profit margins as compared to the comparable period of the prior year which included a greater proportion of license fees that does not have a cost of manufacturing.",
            "type": "paragraph"
        },
        {
            "id": 178,
            "context": "Operating expenses:\n\n| For the Nine Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Operating expenses: |\n| Research and development | $ | 5,165,684 | $ | 3,775,107 | $ | 1,390,577 | 37 | % |\n| General and administrative | 4,906,187 | 4,356,752 | 549,435 | 13 | % |\n| Non-cash compensation | 107,592 | 24,325 | 83,267 | 342 | % |\n| Depreciation and amortization | 999,059 | 933,531 | 65,528 | 7 | % |\n| Total operating expenses | $ | 11,178,522 | $ | 9,089,715 | $ | 2,088,807 | 23 | % |",
            "type": "table"
        },
        {
            "id": 179,
            "context": "Operating expenses consist of research and development costs, general and administrative costs, non-cash compensation and depreciation and amortization expenses. Operating expenses for the nine months ended December 31, 2023 increased by $2.1 million, or 23%, to $11.2 million as compared to $9.1 million for the corresponding period in the prior fiscal year, largely due to an increase in research and development of $1.4 million and general and administrative expenses of $0.5 million.",
            "type": "paragraph"
        },
        {
            "id": 180,
            "context": "Research and development costs during the nine months ended December 31, 2023 were $5.2 million, an increase of $1.4 million, or 37%, from approximately $3.8 million of such costs for the comparable period of the prior year. The increase was a result of the timing and nature of product development activities during the nine months ended December 31, 2023 as compared to the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 181,
            "context": "General and administrative expenses for the nine months ended December 31, 2023 were $4.9 million as compared to $4.4 million for the corresponding period in the prior fiscal year, an increase of $0.5 million or approximately 13%, largely due to an increased human resource headcount and costs as compared to the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 182,
            "context": "Non-cash compensation expense for the nine months ended December 31, 2023 was $0.1 million as compared to $0.02 million for the comparable period of the prior fiscal year, an increase of $0.1 million or approximately 342%, with such increase being attributed to the issuance to employees of options to purchase Common Stock during the current fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 183,
            "context": "Depreciation and amortization expenses from the nine months ended December 31, 2023 were $1.0 million, which was virtually unchanged from $0.9 million in such costs for the comparable period of the prior fiscal year. As a result of the foregoing, our income from operations during the nine months ended December 31, 2023 was $7.1 million, compared to income from operations of $4.1 million for the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 184,
            "context": "Other income (expense):\n\n| For the Nine Months Ended December 31, | Change |\n| 2023 | 2022 | Dollars | Percentage |\n| Other income (expense): |\n| Change in fair value of derivative financial instruments - warrants | $ | (5,075,489 | ) | $ | 561,070 | $ | (5,636,559 | ) | (1,005 | )% |\n| Change in fair value of stock-based liabilities | (4,921,376 | ) | \u2014 | (4,921,376 | ) | 100 | % |\n| Interest expense and amortization of debt issuance costs | (371,478 | ) | (782,221 | ) | 410,743 | (53 | )% |\n| Gain from settlement agreements | 1,761,792 | \u2014 | 1,761,792 | \u2014 | % |\n| Gain on sale of ANDA | \u2014 | 1,000,000 | (1,000,000 | ) | (100 | )% |\n| Interest income | 16,085 | 187 | 15,898 | 8,502 | % |\n| Other (expense) income, net | $ | (8,590,466 | ) | $ | 779,036 | $ | (9,369,502 | ) | (1,203 | )% |",
            "type": "table"
        },
        {
            "id": 185,
            "context": "Other income (expense) for the nine months ended December 31, 2023 was an other expense of $8.6 million, a decrease of $9.4 million from an other income of $0.8 million for the comparable period of the prior fiscal year. The decrease was primarily due to a net increases in other expenses of $5.6 million relating to the change in fair value of derivative instruments, and $4.9 million in change in fair value of stock-based liabilities, net decrease in other income of $1.0 million relating to a gain on sale of ANDA in the comparable period of the prior fiscal year that did not occur in the current fiscal year, offset by $1.8 million in gain from settlement agreements in the current year that did not occur in the comparable period of the prior fiscal year, and an increase in other income resulting from a net $0.4 million decrease in interest expense and amortization of debt issuance costs as compared to the comparable period of the prior fiscal year. Please note that the change in the fair value of derivative instruments and stock-based liabilities is determined in large part by the change in the closing price of the Company\u2019s Common Stock as of the end of the period, as compared to the closing price at the beginning of the period, with a strong inverse relationship between the fair value of our derivatives instruments and stock-based liabilities and decreases in the closing price of the Company\u2019s Common Stock. The decrease in interest expense associated with the loans payable is due in large part to the Company paying off the principal balance of the EWB loan during the fiscal year ended March 31, 2023, resulting in no interest on the EWB loan incurred for the nine months ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 186,
            "context": "As a result of the foregoing, our net loss before income taxes for the nine months ended December 31, 2023 was $1.5 million, compared to net income before income taxes of $4.8 million for the comparable period of the prior fiscal year.",
            "type": "paragraph"
        },
        {
            "id": 187,
            "context": "Liquidity and Capital Resources\nCapital Resources\n\n| December 31, 2023 | March 31, 2023 | Change |\n| Current assets | $ | 37,156,502 | $ | 21,510,297 | $ | 15,646,205 |\n| Current liabilities | $ | 19,158,799 | $ | 7,833,637 | $ | 11,325,162 |\n| Working capital | $ | 17,997,703 | $ | 13,676,660 | $ | 4,321,043 |",
            "type": "table"
        },
        {
            "id": 188,
            "context": "Our working capital (total current assets less total current liabilities) increased by $4.3 million from $13.7 million as of March 31, 2023 to $18.0 million as of December 31, 2023, with such increase being primarily related to the increase in finished goods inventory and accounts receivable, associated with increased customer orders during the nine months ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 189,
            "context": "Summary of Cash Flows:\n\n| For the Nine Months Ended December 31, |\n| 2023 | 2022 |\n| Net cash (used in) provided by operating activities | $ | (5,341,537 | ) | $ | 370,021 |\n| Net cash used in investing activities | $ | (406,007 | ) | $ | (5,200,407 | ) |\n| Net cash provided by financing activities | $ | 3,747,073 | $ | 14,204,231 |",
            "type": "table"
        },
        {
            "id": 190,
            "context": "Net cash used in operating activities for the nine months ended December 31, 2023 was $5.3 million, which included, without limitation, net income of $16.8 million, increased by depreciation and other non-cash expenses totaling $10.1 million and reduced by increases in accounts receivable and inventory totaling $17.9 million.",
            "type": "paragraph"
        },
        {
            "id": 191,
            "context": "Net cash used in investing activities for the nine months ended December 31, 2023 was comprised of purchases of property and equipment of approximately $0.4 million. Net cash provided by financing activities was $3.7 million for the nine months ended December 31, 2023 which consisted primarily of proceeds from related party loans payable totaling $4.0 million offset by payments of bond and loan principal totaling $0.3 million.",
            "type": "paragraph"
        },
        {
            "id": 192,
            "context": "Caskey Promissory Note On June 30, 2023, the Company entered into a collateralized promissory note with Davis Caskey (the \u201cCaskey Promissory Note\u201d). The Caskey Promissory Note has a principal balance of $1,000,000 and an interest rate of 9% for the first year and 10% for an optional second year. The Caskey Promissory Note is subject to the same covenants as are contained in the Hakim Promissory Note. The proceeds will be used for working capital and other business purposes. The original maturity date of the Caskey Promissory Note is June 30, 2024, with an optional second year extension. The second year extension must be exercised by both parties 60 days prior to the original maturity date.",
            "type": "paragraph"
        },
        {
            "id": 193,
            "context": "Hakim Promissory Note The Company has entered into a collateralized promissory note with individual lenders with rates comparable to the EWB Term Loan but with fewer restrictive covenants (the \u201cHakim Promissory Note\u201d). These covenants include filing timely tax returns and financial statements, and an agreement not to sell, lease, or transfer a substantial portion of the Company\u2019s assets during the term of the Hakim Promissory Note. On June 2, 2023, the Company entered into a Promissory Note with Nasrat Hakim, CEO and Chairman of the Board of Directors, pursuant to which the Company borrowed funds in the aggregate principal amount of $3,000,000. The Hakim Promissory Note has an interest rate of 9% for the first year and 10% for an optional second year and the proceeds will be used for working capital and other business purposes. The original maturity date of the Hakim Promissory Note is June 2, 2024, with an optional second year extension. The second year extension must be exercised by both parties 60 days prior to the original maturity date.",
            "type": "paragraph"
        },
        {
            "id": 194,
            "context": "East West Bank On April 2, 2022, the Company and Elite Labs entered into a Loan and Security Agreement (the \u201cEWB Loan Agreement\u201d) with East West Bank (\u201cEWB\u201d). Pursuant to the EWB Loan Agreement, the Company and Elite Labs received one term loan for a principal amount of $12,000,000 (the \u201cEWB Term Loan\u201d) and a revolving line of credit up to $2,000,000 (the \u201cEWB Revolver,\u201d together with the \u201cEWB Term Loan,\u201d the EWB Loans\u201d), each of which shall be used for working capital. As of March 31, 2023, the principal and interest on the EWB Term Loan has been paid in full by the Company and the EWB Loan Agreement is terminated.",
            "type": "paragraph"
        },
        {
            "id": 195,
            "context": "On July 1, 2022, the EWB provided a mortgage loan (\u201cEWB Mortgage Loan\u201d) in the amount of $2.55 million for the purchase of the property at 135-137 Ludlow Avenue, which was formerly a lease held by the Company. The EWB Mortgage Loan matures in 10 years and bears interest at a rate of 4.75% fixed for 5 years then adjustable at WSJP plus 0.5% with floor rate of 4.5%. The total transaction costs associated with the EWB Mortgage Loan incurred as of December 31, 2023, were $13,251, which are being amortized on a monthly basis over ten years, beginning in July 2022. The EWB Mortgage Loan contains customary representations, warranties and covenants. These covenants include maintaining a minimum debt coverage ratio of 1.50 to 1.00 tested annually and a minimum trailing 12-month debt coverage ratio of 1.50 to 1.00. As of December 31, 2023, and through the date of filing of this quarterly report on Form 10-Q, the Company was not aware of the existence of any violations of financial covenants included in the EWB Mortgage Loan.",
            "type": "paragraph"
        },
        {
            "id": 196,
            "context": "Lincoln Park Capital \u2013 July 8, 2020 Purchase Agreement On July 8, 2020, the Company entered into a purchase agreement (the \u201c2020 LPC Purchase Agreement\u201d), and a registration rights agreement, with Lincoln Park Capital Fund, LLC (\u201cLincoln Park\u201d), pursuant to which Lincoln Park has committed to purchase up to $25.0 million of the Company\u2019s Common Stock, $0.001 par value per share, from time to time over the term of the 2020 LPC Purchase Agreement, at the Company\u2019s direction. The 2020 LPC Purchase Agreement expired on August 1, 2023.",
            "type": "paragraph"
        },
        {
            "id": 197,
            "context": "During the three and nine months ended December 31, 2023 and 2022, the Company did not issue any shares of Common Stock to Lincoln Park.\nRecent Developments On December 12, 2023, the Company announced the first shipment of generic Adderall XR\u00ae to its distribution and marketing partner Prasco, LLC (\u201cPrasco\u201d). The Company has a non-exclusive Manufacturing, Supply and Distribution Agreement with Prasco, and Burel Pharmaceuticals, LLC to market Elite\u2019s generic version of Adderall\u00ae XR in the United States. Elite\u2019s product is co-owned with Mikah Pharma.",
            "type": "paragraph"
        },
        {
            "id": 198,
            "context": "As a smaller reporting company, we are not required to provide the information required by this Item.\n\nEvaluation of Disclosure Controls and Procedures The term \u201cdisclosure controls and procedures,\u201d as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC\u2019s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company\u2019s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2023 at the reasonable assurance level.",
            "type": "paragraph"
        },
        {
            "id": 199,
            "context": "Management\u2019s Report on Internal Control Over Financial Reporting Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company\u2019s assets that could have a material effect on the financial statements.",
            "type": "paragraph"
        },
        {
            "id": 200,
            "context": "Internal control over financial reporting may not prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.",
            "type": "paragraph"
        },
        {
            "id": 201,
            "context": "Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled \u201cInternal Control\u2014Integrated Framework (2013)\u201d published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2023 at the reasonable assurance level.",
            "type": "paragraph"
        },
        {
            "id": 202,
            "context": "Changes in Internal Controls Over Financial Reporting\nThere were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the period covered by this Quarterly Report.\n\nPART II - OTHER INFORMATION\n\nPending Litigation On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic Oxycontin and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. Elite obtained agreement with Purdue to stay the litigation for six months. Elite\u2019s launch of a generic Oxycontin will depend on the approval by the FDA and the outcome of various litigations involving Purdue or the expiry of the patents listed on the Orange Book.",
            "type": "paragraph"
        },
        {
            "id": 203,
            "context": "There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023, except as set forth in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023.",
            "type": "paragraph"
        },
        {
            "id": 204,
            "context": "None.\n\nITEM 3. DEFAULTS UPON SENIOR SECURITIES\nNone.\n\nNot applicable.\n During the fiscal quarter ended December 31, 2023, none of the Company\u2019s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).",
            "type": "paragraph"
        },
        {
            "id": 205,
            "context": "| Exhibit No. | Description |\n| 31.1 | Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)* |\n| 31.2 | Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)* |\n| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** |\n| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** |\n| 101.INS | Inline XBRL Instance Document |\n| 101.SCH | Inline XBRL Taxonomy Schema Document |\n| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |\n| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |\n| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |\n| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |\n| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |",
            "type": "table"
        },
        {
            "id": 206,
            "context": "* Filed herewith.\n** Furnished herewith.\n\nSIGNATURES\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n| ELITE PHARMACEUTICALS, INC. |\n| February 14, 2024 | By: | /s/ Nasrat Hakim |\n| Nasrat Hakim Chief Executive Officer, President and Chairman of the Board of Directors (Principal Executive Officer) |\n| February 14, 2024 | By: | /s/ Carter Ward |\n| Carter Ward Chief Financial Officer (Principal Accounting and Financial Officer) |",
            "type": "table"
        },
        {
            "id": 207,
            "context": "",
            "type": "paragraph"
        }
    ],
    "html_tables": [
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_303_111_ztkbD9v6jAT\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)\"> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49D_20231231_zuqgknwc4WSl\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; text-align: center; font-weight: bold\">\u00a0</td><td style=\"padding-bottom: 1.5pt; text-align: center; font-weight: bold\">\u00a0</td> <td colspan=\"2\" id=\"xdx_494_20230331_zIrLhUBErMa6\" style=\"border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; text-align: center; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: center; font-weight: bold\">ASSETS</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--AssetsCurrentAbstract_i01B\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Current assets:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzLZF_zxtZcAs1JEZ4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; width: 60%\">Cash</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 5,816,211 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 7,832,247 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_pp0p0_maACzLZF_zmQ9011ZPrK7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Accounts receivable, net of allowance for expected credit losses of $<span id=\"xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_z7UePjR7cCl8\" title=\"Allowance for doubtful accounts receivable, current\"> 194,600 </span> and $<span id=\"xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230331_zwVJa84YGsL8\" title=\"Allowance for doubtful accounts receivable, current\"> 0 </span> as of December 31, 2023 and March 31, 2023, respectively</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 16,009,614 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,094,549 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--InventoryNet_i02I_pp0p0_maACzLZF_zspHWcWwyHd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Inventory</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,325,041 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 9,550,716 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzLZF_z2WbRWrLQcpd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; padding-left: 10pt; text-align: left\">Prepaid expenses and other current assets</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,005,636 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,032,785 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzLZF_maAzQPq_zSP4JVIrRpsc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left\">Total current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 37,156,502 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 21,510,297 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 0pt\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzQPq_zwPzKInvObqf\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Property and equipment, net of accumulated depreciation of $<span id=\"xdx_903_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20231231_z5TVVoA3yy63\" title=\"Accumulated depreciation\"> 15,578,471 </span> and $<span id=\"xdx_906_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20230331_zV7hixQ1dTa8\" title=\"Accumulated depreciation\"> 14,586,335 </span> respectively</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,095,029 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,426,158 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_pp0p0_maAzQPq_zWPq23UGX0l9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Intangible assets, net of accumulated amortization of $-<span id=\"xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_zVaS9Yeu7bC1\" title=\"Intangible assets accumulated amortization\"><span id=\"xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20230331_zxqRpLRWqf0f\" title=\"Intangible assets accumulated amortization\">  0  </span></span>-</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,341,228 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,341,228 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--FinanceLeaseRightOfUseAsset_i01I_pp0p0_maAzQPq_zyGDE3JGchVk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Finance lease - right-of-use asset</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 408,428 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0076\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzQPq_zvkLBYJxijEa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Operating lease - right-of-use asset</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 26,231 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,062 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_pp0p0_maAzQPq_z6M5xtR8mOG5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Deferred income tax asset</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 20,233,603 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,171,821 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--OtherAssetsAbstract_i01B\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Other assets:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_i02I_pp0p0_maOAzdQo_zOoGXCdtxKo6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Restricted cash - debt service for NJEDA bonds</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 427,999 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 412,434 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--SecurityDeposit_i02I_pp0p0_maOAzdQo_zEeuTEIU4Qnb\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; padding-left: 10pt; text-align: left\">Security deposits</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,259 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 21,018 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--OtherAssets_i02TI_pp0p0_maAzQPq_mtOAzdQo_zmLoswwiK9G4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; padding-left: 20pt; text-align: left\">Total other assets</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 435,258 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 433,452 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--Assets_i01TI_pp0p0_mtAzQPq_zh6U1B5yu4U8\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 2.5pt; padding-left: 20pt; font-weight: bold; text-align: left\">Total assets</td><td style=\"padding-bottom: 2.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: right\"> 74,696,279 </td><td style=\"padding-bottom: 2.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: right\"> 40,896,018 </td><td style=\"padding-bottom: 2.5pt; font-weight: bold; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: center\">LIABILITIES AND SHAREHOLDERS\u2019 EQUITY</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zUcsdL2BPerg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Current liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCz2hP_zcJxkHTxmX6a\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Accounts payable</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 2,890,717 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 2,446,810 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCz2hP_zR2bhZTS23B9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Accrued expenses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 11,884,645 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 5,047,726 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_pp0p0_maLCz2hP_zL3uBJQvnGQa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Deferred revenue, current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,333 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,333 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--SecuredDebtCurrent_i02I_pp0p0_maLCz2hP_z7Ds2V6pEMj3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Bonds payable, current portion, net of bond issuance costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 115,822 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 110,822 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--LoansPayableCurrent_i02I_pp0p0_maLCz2hP_zHT6OsXYrjw\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Loans payable, current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 190,607 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 200,032 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--OtherLoansPayable_i02I_pp0p0_maLCz2hP_zhLDq118Fmph\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Related party loans payable (Note 7)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,000,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0121\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_pp0p0_maLCz2hP_zC3eiMCJ7Fae\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Lease obligation - finance lease, current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 37,444 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0124\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCz2hP_zASQnlA3zs6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; padding-left: 10pt; text-align: left\">Lease obligation - operating lease, current portion</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 26,231 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 14,914 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCz2hP_maLzOlb_zYTZo2Rq49da\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left\">Total current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 19,158,799 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 7,833,637 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Long-term liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--ContractWithCustomerLiabilityNoncurrent_i02I_pp0p0_maLNzS2I_zyjtxypWCihd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Deferred revenue, net of current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 8,889 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 18,890 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--SecuredLongTermDebt_i02I_pp0p0_maLNzS2I_zcfrhCgqaJnl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Bonds payable, net of current portion and bond issuance costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 909,654 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,029,018 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--LongTermLoansPayable_i02I_pp0p0_maLNzS2I_zjqj9rrrmonb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Loans payable, net of current portion and loan costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,407,077 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,532,502 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_pp0p0_maLNzS2I_zui7poC0LSVf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Lease obligation - finance lease, net of current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 200,939 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0145\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--DerivativeLiabilitiesNoncurrent_i02I_pp0p0_maLNzS2I_zrp13rRG8ERk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; padding-left: 10pt; text-align: left\">Derivative financial instruments - warrants</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,597,200 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 521,711 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtLNzS2I_maLzOlb_zAoOrV0ZlVA1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; padding-left: 20pt; text-align: left\">Total long-term liabilities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 9,123,759 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 4,102,121 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--Liabilities_i01TI_pp0p0_mtLzOlb_maLASEzCzD_zSBiX5MK38U6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; font-weight: bold; text-align: left\">Total liabilities</td><td style=\"font-weight: bold\">\u00a0</td> <td style=\"font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; text-align: right\"> 28,282,558 </td><td style=\"font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td style=\"font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; text-align: right\"> 11,935,758 </td><td style=\"font-weight: bold; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--StockholdersEquityAbstract_i01B\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Shareholders\u2019 equity:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--CommonStockValue_i02I_pp0p0_maSEz1U6_zKvfNKZGA0Qc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Common Stock; par value $<span id=\"xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_ziTAvjrHjz66\" title=\"Common stock, par value\"><span id=\"xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331_zLpUQIcspCCf\" title=\"Common stock, par value\">  0.001  </span></span>; <span id=\"xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zyvSvrQr7OY6\" title=\"Common stock, shares authorized\"><span id=\"xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20230331_z2Gafz5fIqLe\" title=\"Common stock, shares authorized\">  1,445,000,000  </span></span> shares authorized; <span id=\"xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20231231_zAb2xwlGihFe\" title=\"Common stock, shares issued\"> 1,017,881,199 </span> and <span id=\"xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20230331_zv0zh3MW1qk8\" title=\"Common stock, shares issued\"> 1,014,015,081 </span> shares issued as of December 31, 2023 and March 31, 2023, respectively; <span id=\"xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zIFggYojIohh\" title=\"Common stock, shares outstanding\"> 1,017,781,199 </span> and <span id=\"xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20230331_zXTuxIXAw2Fc\" title=\"Common stock, shares outstanding\"> 1,013,915,081 </span> shares outstanding as of December 31, 2023 and March 31, 2023, respectively</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,017,885 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,014,019 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEz1U6_z8EQQyLA5Dc3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Additional paid-in capital</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 165,417,811 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 164,750,980 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEz1U6_zikffvzc7DD3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Treasury stock; <span id=\"xdx_903_eus-gaap--TreasuryStockCommonShares_iI_c20231231_z5J38RAmv3Mi\" title=\"Treasury stock, shares\"><span id=\"xdx_905_eus-gaap--TreasuryStockCommonShares_iI_c20230331_zeUa7cYpNusk\" title=\"Treasury stock, shares\">  100,000  </span></span> shares as of December 31, 2023 and March 31, 2023, respectively, at cost</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 306,841 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 306,841 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEz1U6_z5mT96jvVf77\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Accumulated deficit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 119,715,134 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 136,497,898 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40D_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEz1U6_maLASEzCzD_zlcqjdHMVNH3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; padding-left: 20pt; font-weight: bold; text-align: left\">Total shareholders\u2019 equity</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\"> 46,413,721 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\"> 28,960,260 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzCzD_zCyDju1Dsani\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 2.5pt; padding-left: 20pt; font-weight: bold; text-align: left\">Total liabilities and shareholders\u2019 equity</td><td style=\"padding-bottom: 2.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: right\"> 74,696,279 </td><td style=\"padding-bottom: 2.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt; font-weight: bold\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; font-weight: bold; text-align: right\"> 40,896,018 </td><td style=\"padding-bottom: 2.5pt; font-weight: bold; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30A_113_zuy2lTiS1IYa\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20231001__20231231_zBjTVOBAHYu2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_492_20221001__20221231_z5AWqfhgO1Z5\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_495_20230401__20231231_z47YfGZdZRNf\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49F_20220401__20221231_ziVcEiHkPUok\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Three Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--RevenuesAbstract_iB\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Revenue:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_ecustom--RevenueFromManufacturingFees_i01_pp0p0_maRFCWCz1He_zivOPR4sQRB4\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 44%; text-align: left\">Manufacturing fees</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 14,791,110 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 7,798,159 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 36,208,217 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 21,312,663 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_ecustom--RevenueFromLicensingFees_i01_pp0p0_maRFCWCz1He_zyhZEuwIIK9j\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Licensing fees</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 747,690 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,451,907 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,467,844 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 4,200,888 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01T_pp0p0_mtRFCWCz1He_maGPz7FB_zgHuB0yMZpW4\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left\">Total revenue</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 15,538,800 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 9,250,066 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 38,676,061 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,513,551 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--CostOfRevenue_msGPz7FB_zhiCu3Q03a4h\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; padding-bottom: 1.5pt\">Cost of manufacturing</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 8,497,727 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 4,330,841 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 20,437,354 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 12,360,935 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--GrossProfit_iT_pp0p0_mtGPz7FB_maOILzdN8_zmL44wCHx741\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Gross profit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,041,073 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 4,919,225 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 18,238,707 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 13,152,616 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--OperatingExpensesAbstract_iB\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Operating expenses:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzCQg_zRSamziE9Kl6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Research and development</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,403,790 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,443,361 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 5,165,684 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,775,107 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzCQg_zJPX6JQKsz5h\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">General and administrative</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,711,275 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,186,049 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,906,187 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,356,752 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_i01_pp0p0_maOEzCQg_zX02eZnghePi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Non-cash compensation through issuance of stock options</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 49,815 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,030 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 107,592 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 24,325 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--DepreciationAndAmortization_i01_pp0p0_maOEzCQg_zHNWMwv0hJ1c\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Depreciation and amortization</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 343,537 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 317,685 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 999,059 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 933,531 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzCQg_msOILzdN8_zscU3EYqGPhb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left; padding-bottom: 1.5pt\">Total operating expenses</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 3,508,417 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,960,125 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 11,178,522 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 9,089,715 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzdN8_maILFCOzIOe_zSVQSfe0Lml3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Income from operations</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 3,532,656 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,959,100 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,060,185 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 4,062,901 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Other income (expense):</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_pp0p0_maNIEzIWt_z3hmV7zqhfQa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Change in fair value of derivative financial instruments - warrants</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 2,417,772 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 372,894 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 5,075,489 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 561,070 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_ecustom--ChangeInFairValueOfStockbasedLiabilities_i01_pp0p0_maNIEzIWt_zsL5Ijnev6h1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Change in fair value of stock-based liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 2,854,556 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0273\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 4,921,376 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0275\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--InterestExpense_i01N_pp0p0_di_msNIEzIWt_zjUOo6kXwZSc\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Interest expense and amortization of debt issuance costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 121,628 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 322,681 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 371,478 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 782,221 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40F_eus-gaap--GainLossRelatedToLitigationSettlement_i01_pp0p0_maNIEzIWt_zS8GE9kfgIMg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Gain from settlement agreements</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,761,792 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0283\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,761,792 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0285\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--GainLossOnDispositionOfAssets_i01_pp0p0_maNIEzIWt_zBWYYwrbTBX9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Gain on sale of ANDA</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0287\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,000,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0289\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,000,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--InvestmentIncomeInterest_i01_pp0p0_maNIEzIWt_zzCDkRPT8W1i\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Interest income</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,249 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 15 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 16,085 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 187 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_maILFCOzIOe_mtNIEzIWt_zZLAaDK0gFFk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left; padding-bottom: 1.5pt\">Other (expense) income, net</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 3,626,915 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,050,228 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 8,590,466 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 779,036 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOzIOe_maNILzd3M_zkXRNIordQCk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">(Loss) income before income taxes</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 94,259 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,009,328 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 1,530,281 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,841,937 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzd3M_zFUflDFYJpql\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Income tax benefit (expense)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 800,613 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 39,250 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 18,313,045 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 50,837 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzd3M_zYJZpywQea4k\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Net income attributable to common shareholders</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 706,354 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 2,970,078 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 16,782,764 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 4,791,100 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--EarningsPerShareBasic_i_pdd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Basic net income per share attributable to common shareholders</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.02 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--EarningsPerShareDiluted_i_pdd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Diluted net income per share attributable to common shareholders</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.02 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.01 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Basic weighted average Common Stock outstanding</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,768,071 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,013,915,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,265,162 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,012,480,115 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Diluted weighted average Common Stock outstanding</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,024,448,445 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,013,915,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,019,511,813 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,012,480,115 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_304_114_z5xnxBCWkAo1\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesJPreferredStockMember_zJEI6Xw8hrpf\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zi8vHRgYhiD7\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJunR8kQpuC8\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zQ0n4t2xGNud\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zQsTdA0VW7Fd\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B4_z1DWsXtm7Yd2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Series J Preferred Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Common Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\"><b>Additional</b></p> <p style=\"margin-top: 0; margin-bottom: 0\"><b>Paid-In</b></p></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Treasury Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><b>Accumulated</b></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\"><b>Total</b></p> <p style=\"margin-top: 0; margin-bottom: 0\"><b>Shareholders\u2019</b></p></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Capital</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Deficit</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Equity</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_43D_c20230401__20230630_eus-gaap--StockholdersEquity_iS_z0eNi13haZ7b\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 28%; font-weight: bold\">Balance as of April 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_ztCRV6yutigf\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0344\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0337\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrp5gK1Fxs7g\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 1,014,019 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 164,750,980 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zsBP7w5fXHH\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\">( 306,841 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\">( 136,497,898 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 28,960,260 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_zdDXerKOsGy2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0350\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0351\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0352\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0353\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,141,809 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,141,809 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zhq3N1rd6cOk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0357\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0358\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 15,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0360\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0361\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 15,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_43F_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zsyFuEHPRiPa\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at June 30, 2023</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--SharesOutstanding_iS_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zxYmrJjvSgSa\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0371\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0364\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--SharesOutstanding_iS_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5spATik9yx5\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,765,980 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--SharesOutstanding_iS_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zGR0wx8ajhd6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 135,356,089 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 30,117,069 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_z4uTPNLAXLw8\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0377\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0378\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0379\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0380\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,934,601 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,934,601 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zRRrAME3iERc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0384\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0385\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 42,777 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0387\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0388\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 42,777 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_43B_c20231001__20231231_eus-gaap--StockholdersEquity_iS_zEPXjxVtumqh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at September 30, 2023</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iS_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_ze96uzUvB1d8\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0398\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0391\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--SharesOutstanding_iS_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMYaBKMQksxg\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,808,757 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iS_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z1TmCUYLAU0a\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 120,421,488 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 45,094,447 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zL700A0VBKvi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued in satisfaction of accrued director salaries</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0404\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp7NZkSCmdK2\" style=\"text-align: right\" title=\"Shares issued in satisfaction of accrued director salaries, shares\"> 1,642,971 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,643 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 250,224 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0407\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0408\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 251,867 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zqwDymMhmtsa\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued in satisfaction of accrued consultant fees</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0413\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDCQadKFOc36\" style=\"text-align: right\" title=\"Shares issued in satisfaction of accrued consultant fees, shares\"> 2,223,147 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,223 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 309,015 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0416\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0417\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 311,238 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_zC2NZYLDHFX5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0422\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0423\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0424\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0425\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 706,354 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 706,354 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_znnvqkDfsGY7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0429\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0430\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 49,815 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0432\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0433\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 49,815 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_439_c20231001__20231231_eus-gaap--StockholdersEquity_iE_zCphK2SE1ng6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at December 31, 2023</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--SharesOutstanding_iE_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z3JoNdUSRd3i\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0443\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0436\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--SharesOutstanding_iE_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlpEkIPN7VCf\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,017,881,199 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,017,885 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 165,417,811 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--SharesOutstanding_iE_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zXzhvmODnuZg\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 119,715,134 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 46,413,721 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Series J Preferred Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Common Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><b>Additional Paid-In</b></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Treasury Stock</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><b>Accumulated</b></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"text-align: center\"><b>Total Shareholders\u2019</b></td><td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Capital</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Shares</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Deficit</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"text-align: center; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"> Equity</td><td style=\"text-align: center; padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_436_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zjX54ItvWUwb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 28%; font-weight: bold\">Balance as of April 1, 2022</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zXXWdKSVXrr7\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0456\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 4%; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0449\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8KmK1dOnm6\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"> 1,011,381,988 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 1,011,385 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 164,577,227 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z8vNDvII7sDg\" style=\"width: 4%; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\">( 306,841 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\">( 140,059,744 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 4%; text-align: right\"> 25,222,027 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_zx600oQ3sEa4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0462\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0463\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0464\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0465\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 305,883 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 305,883 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zzfy0C6S18Sg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0469\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0470\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,322 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0472\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0473\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,322 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_435_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zQxYEwHMx2Jj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at June 30, 2022</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--SharesOutstanding_iS_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zjDXHC1GCg6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0483\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0476\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--SharesOutstanding_iS_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlZBf6Jj0IQ4\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,011,381,988 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,011,385 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,582,549 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--SharesOutstanding_iS_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zEilBqtVEkTc\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 139,753,861 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 25,533,232 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--NetIncomeLoss_zoK7Z0ILtMcj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0489\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0490\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0491\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0492\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,515,139 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,515,139 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zPdrbuHvnFel\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0496\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0497\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 5,974 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0499\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0500\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 5,974 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zQQc26eo9mz1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Shares issued in payment of director salaries</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0503\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZmlgKMCPx2\" style=\"text-align: right\" title=\"Shares issued in payment of director salaries, shares\"> 1,378,608 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,379 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 58,621 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0506\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0507\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 60,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zBs2PoieBK7e\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Shares issued in payment of consultant fees</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0512\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjt3EnfZZ88\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Shares issued in payment of consultants, shares\"> 1,254,485 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,255 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 75,807 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0515\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0516\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 77,062 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_43C_c20221001__20221231_eus-gaap--StockholdersEquity_iS_zpZJ82mDmel5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at September 30, 2022</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zDBWCRWaQ8ya\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0528\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0521\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkRyRyyY4frj\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,722,951 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zzKNsflId1Ba\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 138,238,722 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 27,191,407 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_439_c20221001__20221231_eus-gaap--StockholdersEquity_iS_zvBRTK0u75pc\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z0D6iIeAuIa3\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0541\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0534\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKFXW75386U6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,722,951 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--SharesOutstanding_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zJsuQldA2AF5\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 138,238,722 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 27,191,407 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--NetIncomeLoss_zxOyEEw1rXLi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0547\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0548\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0549\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0550\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,970,078 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,970,078 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--NetIncomeLoss_zRv7TP2DBjbd\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Net income (Loss)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0554\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0555\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0556\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u2014</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0557\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,970,078 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,970,078 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zekNcTJGzDR6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0561\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0562\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 13,029 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0564\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0565\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 13,029 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_433_c20221001__20221231_eus-gaap--StockholdersEquity_iE_zbyL62PhGzZd\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance at December 31, 2022</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zvKm5KgmkNj7\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0575\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0568\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXO4xOTYe45j\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,735,980 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zEsADAWaiwzi\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 135,268,644 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 30,174,514 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_439_c20221001__20221231_eus-gaap--StockholdersEquity_iE_z2hDPZ6C3fYl\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_z9mejJKMRBwh\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl0588\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0581\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHeo1OxS8WE9\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 1,014,015,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,014,019 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 164,735,980 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--SharesOutstanding_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zqkpAGTWslE8\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Balance, shares\"> 100,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 306,841 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 135,268,644 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 30,174,514 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_307_112_zFHvpK5Khixc\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)\"> <tr style=\"display: none; vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_490_20230401__20231231_za5Oeq0NWMf8\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20220401__20221231_zuZSZTsE8pGl\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td><p style=\"margin-top: 0; margin-bottom: 0\">\u00a0</p> <p style=\"margin-top: 0; margin-bottom: 0\">\u00a0</p></td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzEcD_zpQjpuAve0we\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 60%; text-align: left\">Net income</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 16,782,764 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 4,791,100 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_pp0p0_zwGUVb6cIi5f\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Adjustments to reconcile net income to net cash (used in) provided by operating activities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--DepreciationDepletionAndAmortization_i02_pp0p0_maNCPBUzEcD_zhMZkVapDLRh\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Depreciation and amortization</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 992,136 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 933,531 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--ProvisionForDoubtfulAccounts_i02_pp0p0_maNCPBUzEcD_z0P2ASuRyJVc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Bad debt expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 194,600 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0607\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_pp0p0_maNCPBUzEcD_zAX3L6Gke09c\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Amortization of operating leases - right-of-use assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 18,153 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 61,621 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_ecustom--NoncashCompensationAccrued_i02_pp0p0_maNCPBUzEcD_zTMonjk36tKh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Non-cash compensation accrued</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 563,105 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 430,778 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_pp0p0_di_msNCPBUzEcD_zQwIwNbyPcTf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Change in fair value of derivative financial instruments - warrants</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 5,075,489 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 561,070 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_400_ecustom--ChangeInFairValueOfStockbasedLiabilities_i02N_pp0p0_di_msNCPBUzEcD_zJ5kHrU2KYgf\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Change in fair value of stock-based liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,921,376 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0619\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--GainLossRelatedToLitigationSettlement_i01N_pp0p0_di_maNIEzIWt_msNCPBUzEcD_zCpyDdFxSQKk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Gain on settlement of Common Stock to consultant</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 1,761,792 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0622\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--StockOptionPlanExpense_i02_pp0p0_maNCPBUzEcD_zFTWqbnkPN8b\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Non-cash compensation through the issuance of employee stock options</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 107,592 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 24,325 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_ecustom--NoncashRentExpenseAndLeaseAccretion_i02_pp0p0_maNCPBUzEcD_zpIsrA7q8QW7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Non-cash rent expense and lease accretion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0627\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 602 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_ecustom--DeferredRevenueExpenses_i02N_pp0p0_di_msNCPBUzEcD_zGs1KmCyFQDg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Deferred revenue</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 10,001 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 10,003 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Change in operating assets and liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_pp0p0_di_msNCPBUzEcD_za2FPWzv7bpj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left\">Accounts receivable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 13,109,665 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 2,487,930 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i03N_pp0p0_di_msNCPBUzEcD_zdhz90D6rwsj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt\">Inventory</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 4,774,325 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 1,860,688 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzEcD_zdvGiCrO5Keg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left\">Prepaid expenses and other current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 40,908 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 581,113 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_408_ecustom--IncreaseDecreaseInDeferredIncomeTaxAssets_i03N_pp0p0_di_msNCPBUzEcD_zScXeYjkIG97\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left\">Deferred income tax asset</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 18,061,782 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0646\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_pp0p0_maNCPBUzEcD_zKeaK43v02Vf\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left\">Accounts payable, accrued expenses and other current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,702,825 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 309,950 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40F_ecustom--IncreaseDecreaseInFinanceLeaseLiability_i03_pp0p0_maNCPBUzEcD_z9Vgm25VIm8e\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left\">Interest expense of finance lease liability</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 2,915 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0652\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pp0p0_maNCPBUzEcD_z2wNfUq0yPE4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt; text-align: left; padding-bottom: 1.5pt\">Lease obligations - operating leases</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 20,005 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 61,182 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i03T_pp0p0_mtNCPBUzEcD_maCCERCzWoh_zq94HVL83fKe\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 30pt; text-align: left; padding-bottom: 1.5pt\">Net cash (used in) provided by operating activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 5,341,537 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 370,021 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzCE4_zCIYAITDrzTa\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Purchase of property and equipment</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 406,007 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 5,200,407 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzCE4_maCCERCzWoh_z2YePJpi0nPk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left; padding-bottom: 1.5pt\">Net cash used in investing activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 406,007 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 5,200,407 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--RepaymentsOfFirstMortgageBond_i01N_pp0p0_di_msNCPBUz2Rr_zqLhCIXyTi66\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Payment of bond principal</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 125,000 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 115,000 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_405_eus-gaap--ProceedsFromRelatedPartyDebt_i01_pp0p0_maNCPBUz2Rr_zqEK5NuDOBuj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Proceeds from related party loans payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 4,000,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0676\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUz2Rr_zi8sLf7C4si9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Proceeds from loans payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0678\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,550,001 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_ecustom--ProceedsFromAmortizationOfFinanceLeasesRightofuseAssets_i01_pp0p0_maNCPBUz2Rr_zs8dcGnsAOI2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Amortization of finance leases - right-of-use assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,923 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0682\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--PaymentsOfLoanCosts_i01N_pp0p0_di_msNCPBUz2Rr_zuTUzrUej1qj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Loan payments</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 134,850 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 230,770 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz2Rr_maCCERCzWoh_z4bqGp7OrHSl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; text-align: left; padding-bottom: 1.5pt\">Net cash provided by financing activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 3,747,073 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 14,204,231 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzWoh_z1jzgWWulHmb\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Net change in cash and restricted cash</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 2,000,471 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 9,373,845 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Cash and restricted cash, beginning of period</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 8,244,681 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 8,940,396 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zfcOlgWmaMab\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Cash and restricted cash, end of period</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 6,244,210 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 18,314,241 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zA3CJXXPlM78\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Supplemental disclosure of cash and non-cash transactions:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--InterestPaidNet_i01_z0Pdyv4ZUSKe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Cash paid for interest</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 119,412 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 782,221 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--IncomeTaxesPaidNet_i01_zyFAtv0I6Md2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Cash paid for income taxes</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 292,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 127,522 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_ecustom--StockIssuedInSatisfactionOfAccruedDirectorsSalariesAndConsultantFees_i01_zzkK5R5ZCrC9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Stock issued in satisfaction of accrued directors salaries and consultant fees</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 563,105 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 137,067 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_ecustom--RecognitionOfRightOfUseAssetAndLeaseLiabilities_i01_zWCIxcaoNtN3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Recognition of right of use asset and lease liabilities entered into</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 272,620 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0712\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--RestrictedCashAndCashEquivalentsAbstract_iB_z6RXjTCptchb\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; text-align: left\">Reconciliation of cash and restricted cash</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_pp0p0\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Cash</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 5,816,211 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 17,909,077 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_i01E_pp0p0\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Restricted cash - debt service for NJEDA bonds</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 427,999 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 405,164 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_pp0p0\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Total cash and restricted cash shown in statement of cash flows</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 6,244,210 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 18,314,241 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Three Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">NDA:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"display: none; vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Manufacturing fees</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_zUkc6YqPnkS3\" style=\"text-align: right\" title=\"Manufacturing fees\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b><span style=\"-sec-ix-hidden: xdx2ixbrl0740\">-</span></b></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>-</b></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_zuKFFD5JEyHb\" style=\"text-align: right\" title=\"Manufacturing fees\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b><span style=\"-sec-ix-hidden: xdx2ixbrl0742\">-</span></b></span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>-</b></span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Licensing fees</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zmufbXOIwR2j\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"><span style=\"-sec-ix-hidden: xdx2ixbrl0744\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zVluuC4XcfU4\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"><span style=\"-sec-ix-hidden: xdx2ixbrl0746\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zH0xWbjGrWub\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"><span style=\"-sec-ix-hidden: xdx2ixbrl0748\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zjkOS3a8TWya\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"><span style=\"-sec-ix-hidden: xdx2ixbrl0750\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Total NDA revenue</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember_z0qE8gGzPmf\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total NDA revenue\"><span style=\"-sec-ix-hidden: xdx2ixbrl0752\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember_zE0HQk6HaAUa\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total NDA revenue\"><span style=\"-sec-ix-hidden: xdx2ixbrl0754\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember_zhRPjBAz10ta\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total NDA revenue\"><span style=\"-sec-ix-hidden: xdx2ixbrl0756\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--NewDrugApplicationsMember_znR3WsFbnqp5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total NDA revenue\"><span style=\"-sec-ix-hidden: xdx2ixbrl0758\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">ANDA:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 44%; text-align: left\">Manufacturing fees</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_zmOaMdA5PEOh\" style=\"width: 10%; text-align: right\" title=\"Manufacturing fees\"> 14,791,110 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_zeS6Qs2gycOe\" style=\"width: 10%; text-align: right\" title=\"Manufacturing fees\"> 7,798,159 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_z0fqNlcrT83l\" style=\"width: 10%; text-align: right\" title=\"Manufacturing fees\"> 36,208,217 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--ManufacturingMember_zLh6BaJduoFa\" style=\"width: 10%; text-align: right\" title=\"Manufacturing fees\"> 21,312,663 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Licensing fees</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_z4eW6sjP8Mrl\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"> 747,690 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zeq47AKGLrra\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"> 1,451,907 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_zW0IJMgaiDGe\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"> 2,467,844 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember__srt--ProductOrServiceAxis__custom--LicensingMember_z2UZvXaklkj3\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Licensing fees\"> 4,200,888 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Total ANDA revenue</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember_zApXPf6dnH91\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total ANDA revenue\"> 15,538,800 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember_z6fiubcoJ2Wf\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total ANDA revenue\"> 9,250,066 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember_znFZ8HY157Db\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total ANDA revenue\"> 38,676,061 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember_zVrfkHA0fhX5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total ANDA revenue\"> 25,513,551 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Total revenue</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20231001__20231231_zuHhDebNMcz3\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total revenue\"> 15,538,800 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20221001__20221231_zHkfvpHQ9jL3\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total revenue\"> 9,250,066 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20231231_zIwYzVfBhkf7\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total revenue\"> 38,676,061 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20221231_ztrQu7XbJDod\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total revenue\"> 25,513,551 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td colspan=\"17\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Estimated Useful Life</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Gross Carrying Amount</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Impairment losses</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Accumulated Amortization</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Net Book Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 25%; text-align: left\">Patent application costs</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 13%; text-align: center\">*</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_z2Jc7P888nBb\" style=\"width: 11%; text-align: right\" title=\"Gross Carrying Amount\"> 289,039 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_983_ecustom--FinitelivedIntangibleAssetsImpairment_d0_c20230401__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_z65iNJm73I85\" style=\"width: 11%; text-align: right\" title=\"Reductions\"> \u2014 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zKSZOrwrXLUl\" style=\"width: 11%; text-align: right\" title=\"Accumulated Amortization\"><span style=\"-sec-ix-hidden: xdx2ixbrl0818\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zxIyFZB3djIj\" style=\"width: 11%; text-align: right\" title=\"Net Book Value\"> 289,039 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">ANDA acquisition costs</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\"><span id=\"xdx_905_eus-gaap--ImpairedIntangibleAssetDescription_c20230401__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zAfaf3zccJWd\" title=\"Estimated Useful Life\"> Indefinite </span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zvQUVfIEAk4d\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Gross Carrying Amount\"> 6,052,189 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_ecustom--FinitelivedIntangibleAssetsImpairment_d0_c20230401__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zosCi0KSS4na\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Reductions\"> \u2014 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zSGXqW52GCW7\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Accumulated Amortization\"><span style=\"-sec-ix-hidden: xdx2ixbrl0828\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zMmL9MHkDyge\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Net Book Value\"> 6,052,189 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20231231_z5UiXUB9vbag\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Gross Carrying Amount\"> 6,341,228 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98E_ecustom--FinitelivedIntangibleAssetsImpairment_d0_c20230401__20231231_zyVf5hkIBGi4\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Reductions\"> \u2014 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20231231_zC1k9QUXMvoh\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Accumulated Amortization\"> \u2014 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20231231_zdAhmTEc0ned\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Net Book Value\"> 6,341,228 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td> <td colspan=\"17\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Estimated Useful Life</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Gross Carrying Amount</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Impairment losses</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Accumulated Amortization</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Net Book Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 25%; text-align: left\">Patent application costs</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 13%; text-align: center\">*</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zJdUF3uwq8pi\" style=\"width: 11%; text-align: right\" title=\"Gross Carrying Amount\"> 465,684 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_981_ecustom--FinitelivedIntangibleAssetsImpairment_iN_di_c20220401__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zTTyl6gQzZI9\" style=\"width: 11%; text-align: right\" title=\"Reductions\">( 176,645 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zVbi4AQjlAah\" style=\"width: 11%; text-align: right\" title=\"Accumulated Amortization\"><span style=\"-sec-ix-hidden: xdx2ixbrl0844\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationCostsMember_zXmOG6UPfkl3\" style=\"width: 11%; text-align: right\" title=\"Net Book Value\"> 289,039 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">ANDA acquisition costs</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\"><span id=\"xdx_901_eus-gaap--ImpairedIntangibleAssetDescription_c20220401__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zNdaFWLuDDce\" title=\"Estimated Useful Life\"> Indefinite </span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zzFzfDhbac25\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Gross Carrying Amount\"> 6,168,351 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_988_ecustom--FinitelivedIntangibleAssetsImpairment_iN_di_c20220401__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zsHae0ut0ax3\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Reductions\">( 116,162 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zPtCsQApd19g\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Accumulated Amortization\"><span style=\"-sec-ix-hidden: xdx2ixbrl0854\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ANDAAcquisitionCostsMember_zh1PEBUe1rEc\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Net Book Value\"> 6,052,189 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_z78mIz32XqL6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Gross Carrying Amount\"> 6,634,035 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_989_ecustom--FinitelivedIntangibleAssetsImpairment_iN_di_c20220401__20230331_z3zSFb8ENGld\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Reductions\">( 292,807 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20230331_zUGiYugFVSXh\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Accumulated Amortization\"> \u2014 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zyWfgy7jQKb\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Net Book Value\"> 6,341,228 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"display: none; vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20231001__20231231_zVELa1wYd0yj\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20221001__20221231_zKU2K0B89MOk\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49F_20230401__20231231_zIuKdSdQIY8e\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20220401__20221231_z3Rq6PxF3zWd\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Three Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-decoration: underline\">Numerator</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zzdGgqEM9bXb\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 44%; text-align: left\">Net income - basic</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 706,354 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 2,970,078 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 16,782,764 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 10%; text-align: right\"> 4,791,100 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_z5rpHYR4Eou3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Effect of dilutive instrument on net income</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0899\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 372,894 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0901\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 561,070 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_zlQ8DS30FDji\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Net income - diluted</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 706,354 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 3,342,972 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 16,782,764 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 5,352,170 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-decoration: underline\">Denominator</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zPNQ2VWNM0x1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Weighted average shares of Common Stock outstanding - basic</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,014,768,071 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,013,915,081 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,014,265,162 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,012,480,115 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--DilutiveSecurities_zoFHjR0yRr59\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left\">Dilutive effect of stock options and convertible securities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 9,680,374 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0915\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,246,651 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0917\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zM8D7EI6awc3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 2.5pt\">Weighted average shares of Common Stock outstanding - diluted</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,024,448,445 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,013,915,081 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,019,511,813 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,012,480,115 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Net income per share</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--EarningsPerShareBasic_zEKm5UnvEaZk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; padding-bottom: 2.5pt\">Basic</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.02 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--EarningsPerShareDiluted_zW0bXSiFMAB7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; padding-bottom: 2.5pt\">Diluted</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.00 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.02 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 0.01 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0\"><tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in\"></td><td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\">\u25cf</td><td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Level 1 \u2013 Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in\"></td><td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\">\u25cf</td><td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Level 2 \u2013 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in\"></td><td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\">\u25cf</td><td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Level 3 \u2013 Inputs that are unobservable for the asset or liability.</span></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Fair Value Measurement</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount at Fair Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 1</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 2</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 3</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 44%; font-weight: bold\">Balance as of April 1, 2023</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20230401__20231231_zvsim4AdklN9\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"> 521,711 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98E_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjVIgShm6KC8\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0940\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztS2ZELxdDHg\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0942\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zG24DgTkgPP1\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"> 521,711 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Change in fair value of derivative financial instruments - warrants</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230401__20231231_zPaM5Dg4yAA9\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"> 5,075,489 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAoTfn7tTjY\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"><span style=\"-sec-ix-hidden: xdx2ixbrl0948\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziiKZ6gRy6Ch\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"><span style=\"-sec-ix-hidden: xdx2ixbrl0950\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4iD4M1gsLb3\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"> 5,075,489 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance as of December 31, 2023</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20230401__20231231_zpwhhIvMVLl6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"> 5,597,200 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFHZWRgmud93\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0956\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzYdm3Ih4Uv9\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0958\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx53XS4P80M\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"> 5,597,200 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Fair Value Measurement</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount at Fair Value</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 1</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 2</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Level 3</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 44%; font-weight: bold\">Balance as of April 1, 2022</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20220401__20221231_zc5YrwUu3Q85\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"> 936,837 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zumAc5HVTotj\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0964\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwxkANfqVT49\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0966\">\u2014</span></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcbAJLEtHjQ1\" style=\"width: 10%; text-align: right\" title=\"Derivative liabilities, beginning balance\"> 936,837 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Change in fair value of derivative financial instruments - warrants</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220401__20221231_zp9w9hik8ZQ6\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\">( 561,070 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSgGwGPgL44b\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"><span style=\"-sec-ix-hidden: xdx2ixbrl0972\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z8i6H5PckQD9\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\"><span style=\"-sec-ix-hidden: xdx2ixbrl0974\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHW1bntaRokl\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Change in fair value of derivative instruments\">( 561,070 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; padding-bottom: 2.5pt\">Balance as of December 31, 2022</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20220401__20221231_zC5lGvWBB56d\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"> 375,767 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAhE13R3yAph\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0980\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEeMmXLQlLJa\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl0982\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20220401__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqjoQlI2dmVa\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Derivative liabilities, ending balance\"> 375,767 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20231231_zBmXKMdihjb2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49A_20230331_zOADM8FlDDua\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--InventoryFinishedGoods_iI_maINzVRp_zZen0I8ABLa5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Finished goods</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 5,544,848 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 2,352,330 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--InventoryWorkInProcess_iI_maINzVRp_zUXSutCv5by4\" style=\"vertical-align: bottom; background-color: White\"> <td>Work-in-progress</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,247,307 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,791,311 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINzVRp_zVz71hBv3SYc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Raw materials</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,532,886 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 5,407,075 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--InventoryNet_iTI_mtINzVRp_zj25xTGMdLea\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 2.5pt\">Inventory</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 14,325,041 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 9,550,716 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_499_20231231_zOFvVoIB4aZc\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49A_20230331_zOB2DofIE3h2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandBuildingsAndImprovementsMember_zyweaBN0w4vj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Land, building and improvements</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 10,269,297 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 10,768,181 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryManufacturingWarehouseAndTransportationEquipmentMember_zHmZuONSeivc\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Laboratory, manufacturing, warehouse and transportation equipment</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,518,570 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,364,512 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndSoftwareMember_zimxQFvFnPq6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Office equipment and software</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 373,601 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 395,563 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOpsUwtvHRC2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Furniture and fixtures</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 512,032 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 484,237 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDF9_zmXGq5ivypR\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Property and equipment, gross</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,673,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,012,493 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDF9_zaPZ8DGMTD8d\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Less: Accumulated depreciation</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 15,578,471 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 14,586,335 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDF9_z2vTLXKcCdV1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Property and equipment, net</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 10,095,029 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 10,426,158 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20231231_zNlk5y1eCir5\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20230331_zOc55J6uKSD4\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzIQJ_zZnZAC49jKh6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Salaries and fees payable in Common Stock inclusive of the change in fair value of Common stock underlying such liabilities</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"><p style=\"margin: 0\"> 6,934,812 </p></td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 4,125,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCzIQJ_zrf8anqjk9Ll\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Income tax</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1050\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 414,989 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_ecustom--AccruedCodevelopmentProfitSplit_iI_maALCzIQJ_zNhWd88lFh47\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Co-development profit split</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,389,949 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><p style=\"margin: 0\"><span style=\"-sec-ix-hidden: xdx2ixbrl1054\">\u2014</span></p></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_ecustom--AccruedConsultantContractFees_iI_maALCzIQJ_zobtuF11X9D5\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Consultant contract fees</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 193,333 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzIQJ_zNx6wclgiNk8\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Audit fees</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 125,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 125,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_ecustom--AccruedDirectorDues_iI_maALCzIQJ_zexw6vgCaSZ\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Director dues</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 22,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 70,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--LitigationReserveCurrent_iI_maALCzIQJ_zp765CHmFkre\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Legal and professional expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 75,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1066\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzIQJ_z6h7jVV5da35\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Employee bonuses</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 712,384 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1069\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzIQJ_znV2y1Zrna75\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Other accrued expenses</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 615,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 119,404 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzIQJ_zgzgql0VEcRg\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Total accrued expenses</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 11,884,645 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 5,047,726 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-decoration: underline; text-align: left\">Gross bonds payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 60%; text-align: left\">NJEDA Bonds - Series A Notes</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_980_ecustom--BondsPayableGross_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zX9a7YSEAoRh\" style=\"width: 16%; text-align: right\" title=\"NJEDA Bonds - Series A Notes\"> 1,120,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98F_ecustom--BondsPayableGross_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zNC743Y23SK7\" style=\"width: 16%; text-align: right\" title=\"NJEDA Bonds - Series A Notes\"> 1,245,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Less: Current portion of bonds payable (prior to deduction of bond offering costs)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98C_ecustom--BondsPayableCurrentGross_iNI_pp0p0_di_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zhOranSss5O5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Current portion of bonds payable (prior to deduction of bond offering costs)\">( 130,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_ecustom--BondsPayableCurrentGross_iNI_pp0p0_di_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zqoykRYqTpQ\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Current portion of bonds payable (prior to deduction of bond offering costs)\">( 125,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Long-term portion of bonds payable (prior to deduction of bond offering costs)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_985_ecustom--LongTermBondsPayableGross_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zZrMiT9807Jd\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Long-term portion of bonds payable (prior to deduction of bond offering costs)\"> 990,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_986_ecustom--LongTermBondsPayableGross_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zAK6ZWL33Xr7\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Long-term portion of bonds payable (prior to deduction of bond offering costs)\"> 1,120,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Bond offering costs</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_984_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zih6pY9DoBhg\" style=\"text-align: right\" title=\"Bond offering costs\"> 354,454 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_980_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_z4pJ1FoHZRRc\" style=\"text-align: right\" title=\"Bond offering costs\"> 354,454 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Less: Accumulated amortization</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--AccumulatedAmortizationDeferredFinanceCosts_iNI_pp0p0_di_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zUbXoNsXIUeh\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Accumulated amortization\">( 259,930 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--AccumulatedAmortizationDeferredFinanceCosts_iNI_pp0p0_di_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_znOjvGks5Re5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Accumulated amortization\">( 249,294 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Bond offering costs, net</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_982_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zKf9h1ksbaEh\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Bond offering costs, net\"> 94,524 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsSeriesANotesMember_zEXc5sbewIjg\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Bond offering costs, net\"> 105,160 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-decoration: underline; text-align: left\">Current portion of bonds payable - net of bond offering costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Current portions of bonds payable</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_983_ecustom--BondsPayableCurrentGross_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_z17VsHAViSDc\" style=\"text-align: right\" title=\"Current portions of bonds payable\"> 130,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_98F_ecustom--BondsPayableCurrentGross_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_zpk9NuteczVh\" style=\"text-align: right\" title=\"Current portions of bonds payable\"> 125,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Less: Bonds offering costs to be amortized in the next 12 months</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_pp0p0_di_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_zx38zDMISg17\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Bonds offering costs to be amortized in the next 12 months\">( 14,178 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_981_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_pp0p0_di_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_zQWercBxb8Ul\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Bonds offering costs to be amortized in the next 12 months\">( 14,178 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Current portion of bonds payable, net of bond offering costs</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--DebtSecuritiesCurrent_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_z1IvCMDVk1Lj\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Current portion of bonds payable, net of bond offering costs\"> 115,822 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98B_eus-gaap--DebtSecuritiesCurrent_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsCurrentMember_zyqtZ7Xqncva\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Current portion of bonds payable, net of bond offering costs\"> 110,822 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-decoration: underline; text-align: left\">Long term portion of bonds payable - net of bond offering costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Long term portion of bonds payable</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_985_ecustom--LongTermBondsPayableGross_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zg6FtvGbq9nf\" style=\"text-align: right\" title=\"Long term portion of bonds payable\"> 990,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_988_ecustom--LongTermBondsPayableGross_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zFxWL9QdlSWe\" style=\"text-align: right\" title=\"Long term portion of bonds payable\"> 1,120,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 1.5pt\">Less: Bond offering costs to be amortized subsequent to the next 12 months</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--DeferredFinanceCostsNoncurrentNet_iNI_pp0p0_di_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zQwy8V1xS84j\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Bond offering costs to be amortized subsequent to the next 12 months\">( 80,346 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--DeferredFinanceCostsNoncurrentNet_iNI_pp0p0_di_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zkXUs4It6lug\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Less: Bond offering costs to be amortized subsequent to the next 12 months\">( 90,982 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Long term portion of bonds payable, net of bond offering costs</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_985_eus-gaap--LongTermDebt_iI_pp0p0_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zPIuqIb4KMDg\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Long term portion of bonds payable, net of bond offering costs\"> 909,654 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--LongTermDebt_iI_pp0p0_c20230331__us-gaap--LongtermDebtTypeAxis__custom--NjedaBondsNoncurrentMember_zRKKsmjkZTj8\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Long term portion of bonds payable, net of bond offering costs\"> 1,029,018 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"padding-bottom: 1.5pt; font-weight: bold\">Years ending March 31,</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49F_20231231__us-gaap--LongtermDebtTypeAxis__custom--NJEDABondsMember_zXxURucRdPGa\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDzzZi_zRarU30GuTa6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2024</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1153\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDzzZi_zTok15fnZrF6\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 80%; text-align: left\">2025</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\"> 130,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDzzZi_zAEHiILA1s1c\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2026</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 140,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDzzZi_zpBlRDI4ftC5\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2027</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 150,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDzzZi_zZfYjSL5KNP9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2028</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 160,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_iI_maLTDzzZi_zbXoOo6265M8\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt\">Thereafter</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 540,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--LongTermDebt_iTI_mtLTDzzZi_z0Vuuc5wJL63\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 2.5pt\"><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\">Total</span></td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,120,000 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_497_20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zwzKEbUBIPL4\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8Q0nQmjvBT7\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_40C_ecustom--MortgageLoanPayable_iI_zDjBsEsrbTz1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Mortgage loan payable <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--MortgageLoanMember_z8d1jIndAx08\" title=\"Debt interest rate\"><span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230331__us-gaap--LongtermDebtTypeAxis__custom--MortgageLoanMember_zddlO8BRW8w5\" title=\"Debt interest rate\">  4.75  </span></span>% interest and maturing June 2032</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 2,438,958 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 2,472,923 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--LoansPayable_iI_zakrW1hc7uB9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Equipment and insurance financing loans payable, between <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--EquipmentAndInsuranceFinancingLoanMember_zVNyFwCeAKT7\" title=\"Debt interest rate\"><span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--LongtermDebtTypeAxis__custom--EquipmentAndInsuranceFinancingLoanMember_z2iUjLvUQyP5\" title=\"Debt interest rate\">  7.10  </span></span>% and <span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--EquipmentAndInsuranceFinancingLoanMember_zrnjAt7Djgz8\" title=\"Debt interest rate\"><span class=\"xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPQU5TIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_\" id=\"xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--LongtermDebtTypeAxis__custom--EquipmentAndInsuranceFinancingLoanMember_zsiWhEu7ZIee\" title=\"Debt interest rate\">  12.02  </span></span>% interest and maturing between January 2024 and October 2025</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 158,726 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 259,611 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--LoansPayableCurrent_iNI_di_zrFZubaYNQJh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Less: Current portion of loans payable</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 190,607 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 200,032 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40B_eus-gaap--LongTermLoansPayable_iI_ztQu4IdAFbpg\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Long-term portion of loans payable</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 2,407,077 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 2,532,502 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: left; font-weight: bold\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49F_20231231__us-gaap--LongtermDebtTypeAxis__us-gaap--LoansPayableMember_zuPIm7aDwSc5\">\u00a0</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: left; font-weight: bold\">Future principal balances</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold\">Years ending March 31,</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Amount</b></span></td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLPz2Cv_zXwBafJHY3f\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; width: 80%\">2024 (excluding the nine months ended December 31, 2023)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 44,535 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLPz2Cv_zGNtPoMf2jK\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2025</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 186,657 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLPz2Cv_zEITsj0tl2Dl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2026</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 120,748 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLPz2Cv_z5m3AY9VQAZa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2027</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 92,773 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLPz2Cv_z1E5fXtCbmOl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2028</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 94,433 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour_iI_maLPz2Cv_zPq4uqN6v5b\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">2029 and thereafter</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,058,538 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--LongTermDebt_iTI_mtLPz2Cv_zbjpkhp28Mje\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Total remaining principal balance</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,597,684 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold\">Lease</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold\">Classification</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold\">Assets</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 30%\">Finance</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 46%; text-align: left\">Finance lease \u2013 right-of-use asset</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_981_eus-gaap--FinanceLeaseRightOfUseAsset_iI_c20231231_ziUEHqWdbLX2\" style=\"width: 18%; text-align: right\" title=\"Finance lease- right-of-use asset\"> 408,428 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\">Operating</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: left; padding-bottom: 1.5pt\">Operating lease \u2013 right-of-use asset</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zCINCwGruxI5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Operating lease- right-of-use asset\"> 26,231 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Total leased assets</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_985_ecustom--LeaseAssets_iI_c20231231_zg9SHNcjP9Y6\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total leased assets\"> 434,659 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold\">Liabilities</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Current</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt\">Finance</td><td>\u00a0</td> <td style=\"text-align: left\">Lease obligation \u2013 finance lease</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_987_eus-gaap--FinanceLeaseLiabilityCurrent_iI_c20231231_zhyUIGiJG5Va\" style=\"text-align: right\" title=\"Lease obligation- finance lease\"> 37,444 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Operating</td><td>\u00a0</td> <td style=\"text-align: left\">Lease obligation \u2013 operating lease</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231_zob2GTljqakk\" style=\"text-align: right\" title=\"Lease obligation- operating lease\"> 26,231 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Long-term</td><td>\u00a0</td> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt\">Finance</td><td>\u00a0</td> <td style=\"text-align: left\">Lease obligation \u2013 finance lease, net of current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20231231_zgDTvhCXKTxc\" style=\"text-align: right\" title=\"Lease obligation-finance lease, net of current portion\"> 200,939 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; padding-bottom: 1.5pt\">Operating</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: left; padding-bottom: 1.5pt\">Lease obligation \u2013 operating lease, net of current portion</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231_zdj26u40LJyd\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Lease obligation-operating lease, net of current portion\"><span style=\"-sec-ix-hidden: xdx2ixbrl1326\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left; padding-bottom: 2.5pt\">Total lease liabilities</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"padding-bottom: 2.5pt\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_981_ecustom--LeaseLiabilities_iI_c20231231_zhlVbOgyijSk\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total lease liabilities\"> 264,614 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold\">Years ending March 31,</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Operating Lease Amount</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Financing Lease Amount</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">Total</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 46%\">2024 (excluding the nine months ended December 31, 2023)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20231231_zFFNEMecsO0j\" style=\"width: 14%; text-align: right\" title=\"Operating Lease Amount 2024\"> 8,087 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20231231_zS6yc6UNWkf9\" style=\"width: 14%; text-align: right\" title=\"Financing Lease Amount 2024\"> 16,286 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_98B_ecustom--LeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20231231_ztKkPXx8XAek\" style=\"width: 14%; text-align: right\" title=\"Total Lease Amount 2024\"> 24,373 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2025</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zwZ7Iglji0sh\" style=\"text-align: right\" title=\"Operating Lease Amount 2025\"> 18,870 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zqOyCYV1DGGc\" style=\"text-align: right\" title=\"Financing Lease Amount 2025\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98C_ecustom--LeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zbgeRXfFTONg\" style=\"text-align: right\" title=\"Total Lease Amount 2025\"> 84,015 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2026</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zQcQYhiKdSN7\" style=\"text-align: right\" title=\"Operating Lease Amount 2026\"><span style=\"-sec-ix-hidden: xdx2ixbrl1360\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zz2DZKz86YA5\" style=\"text-align: right\" title=\"Financing Lease Amount 2026\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_988_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zt0Ej5dwOg09\" style=\"text-align: right\" title=\"Total Lease Amount 2026\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">2027</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zto8lu6WaVGg\" style=\"text-align: right\" title=\"Operating Lease Amount 2027\"><span style=\"-sec-ix-hidden: xdx2ixbrl1366\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zLiGJOjcaKUi\" style=\"text-align: right\" title=\"Financing Lease Amount 2027\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_c20231231_zPpBejvD4NSi\" style=\"text-align: right\" title=\"Total Lease Amount 2027\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">2028</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zm1AvUDE2E9g\" style=\"text-align: right\" title=\"Operating Lease Amount 2028\"><span style=\"-sec-ix-hidden: xdx2ixbrl1372\">\u2014</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zALdXQmWvirh\" style=\"text-align: right\" title=\"Financing Lease Amount 2028\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_982_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_c20231231_zALNlFF1Oyhk\" style=\"text-align: right\" title=\"Total Lease Amount 2028\"> 65,145 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt\">Thereafter</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_zLKSqzddcjWj\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Operating Lease Amount Thereafter\"><span style=\"-sec-ix-hidden: xdx2ixbrl1378\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_zi6bLSqIx3Xf\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Financing Lease Amount Thereafter\"> 43,429 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_989_ecustom--LeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_ztzxJ8aC5Gs8\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total Lease Amount Thereafter\"> 43,429 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Less: interest</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_zWc4Nrnt7Rr9\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Operating Lease Amount Less: interest\">( 727 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_z8eWfcixYaig\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Financing Lease Amount Less: interest\">( 81,911 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_980_ecustom--LeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_zrs0kPFkIZdc\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Total Lease Amount Less: interest\">( 82,638 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; padding-bottom: 2.5pt\">Present value of lease payments</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20231231_zoZHjdLmm7fb\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Operating Lease Amount Present value of lease payments\"> 26,230 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--FinanceLeaseLiability_iI_c20231231_zlrEsg6g4Pp\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Financing Lease Amount Present value of lease payments\"> 238,384 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td id=\"xdx_98B_ecustom--LeaseLiabilities_iI_c20231231_za8XQC5dqhul\" style=\"border-bottom: Black 2.5pt double; text-align: right\" title=\"Total Lease Amount Present value of lease payments\"> 264,614 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold\">Lease Term and Discount Rate</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Remaining lease term (years)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 80%; text-align: left\">Operating leases</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\"><span id=\"xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zm7Pu7Ntgb3e\" title=\"Remaining lease term (years) Operating leases\"> 0.8 </span></td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Finance leases</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_90D_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zRWNyNWMvI8b\" title=\"Remaining lease term (years) Finance leases\"> 4.9 </span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Discount rate</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; text-align: left\">Operating leases</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zrVzhY7Z0BCa\" title=\"Discount rate Operating leases\"> 6.0 </span></td><td style=\"text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; text-align: left\">Finance leases</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span id=\"xdx_90D_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20231231_z7SMByVQt7N3\" title=\"Discount rate Finance leases\"> 12.5 </span></td><td style=\"text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black; text-align: center\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; color: Black; text-align: left\">Fair value of the Company\u2019s Common Stock</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHuXWsAkaXeg\" style=\"width: 16%; color: Black; text-align: right\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 0.1393 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z6yQ4dSXpns8\" style=\"width: 16%; color: Black; text-align: right\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 0.0290 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">Volatility</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb1iNcW1kMa1\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 73.50 </span></td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zuRcwRmEAVMb\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 74.37 </span></td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black\">Initial exercise price</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td id=\"xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zd0YunL89tL1\" style=\"color: Black; text-align: right\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 0.1521 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td id=\"xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z5PadJ9YJwL4\" style=\"color: Black; text-align: right\" title=\"Warrants and Rights Outstanding, Measurement Input\"> 0.1521 </td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left\">Warrant term (in years)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zMAWjzV6IJcb\" title=\"Warrant term (in years)\"> 3.3 </span></td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230331_zgXAvlaxqMr7\" title=\"Warrant term (in years)\"> 4.1 </span></td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Risk free rate</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zC26fi5qSGF9\" title=\"Warrants and rights outstanding, measurement input\"> 4.01 </span></td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zzhfo0yXRGce\" title=\"Warrants and rights outstanding, measurement input\"> 3.55 </span></td><td style=\"color: Black; text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 80%; color: Black\">Balance at March 31, 2023</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--DerivativeLiabilityFairValueOfCollateral_iS_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zaknAmP4g3ej\" style=\"width: 16%; color: Black; text-align: right\" title=\"Beginning balance\"> 521,711 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left; padding-bottom: 1.5pt\">Change in fair value of derivative financial instruments - warrants</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--DerivativeGainLossOnDerivativeNet_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z5ay6NzTgPF5\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Change in fair value of derivative financial instruments - warrants\"> 5,075,489 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; padding-bottom: 2.5pt\">Balance at December 31, 2023</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td id=\"xdx_98C_eus-gaap--DerivativeLiabilityFairValueOfCollateral_iE_c20230401__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zb85ceENi3sf\" style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\" title=\"Ending balance\"> 5,597,200 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 80%; color: Black; text-align: left\">Balance of common stock owed at April 1, 2023</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_986_eus-gaap--AccruedEmployeeBenefitsCurrent_iS_c20230401__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zCeQsI8gZhC4\" style=\"width: 16%; color: Black; text-align: right\" title=\"Balance\"> 60,000 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">Awarded shares</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98B_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20230401__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zDaSr2EBjKg8\" style=\"color: Black; text-align: right\" title=\"Awarded shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl1500\">\u2014</span></td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Change in fair value of stock-based liabilities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_c20230401__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zCD8TeP7rOJ\" style=\"color: Black; text-align: right\" title=\"Change in fair value of non-cash liabilities\"> 191,867 </td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; padding-bottom: 1.5pt\">Issuance of common stock on November 22, 2023</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230401__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zM8zXjlzAVSb\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Issuance of common stock\">( 251,867 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 2.5pt\">Balance of common stock owed at December 31, 2023</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td id=\"xdx_984_eus-gaap--AccruedEmployeeBenefitsCurrent_iE_c20230401__20231231__srt--TitleOfIndividualAxis__srt--DirectorMember_zUBtgfgT5GHg\" style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\" title=\"Balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl1506\">\u2014</span></td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 80%; color: Black; text-align: left\">Balance of common stock owed at April 1, 2023</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_983_ecustom--StockBasedCompensation_iS_c20230401__20231231_zCqoSAogee09\" style=\"width: 16%; color: Black; text-align: right\" title=\"Beginning balance\"> 4,278,333 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">Awarded shares</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_988_ecustom--AwardedShares_c20230401__20231231_zVQfyG2H7Ivk\" style=\"color: Black; text-align: right\" title=\"Awarded shares\"><span style=\"-sec-ix-hidden: xdx2ixbrl1512\">\u2014</span></td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Change in fair value of stock-based liabilities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_982_ecustom--IncreaseDecreaseInStockBasedLiabilities_c20230401__20231231_zW6LxdI2MhFc\" style=\"color: Black; text-align: right\" title=\"Change in fair value of stock-based liabilities\"> 4,729,509 </td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left\">Common stock issued</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--CommonStockIssued_c20230401__20231231_zJyy6qG0Gqj1\" style=\"color: Black; text-align: right\" title=\"Common stock issued\">( 311,238 </td><td style=\"color: Black; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 1.5pt\">Settlement of non-cash liability</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98F_ecustom--SettlementOfNoncashLiability_c20230401__20231231_zFUU0l1ooyb4\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Settlement of non-cash liability\">( 1,761,792 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left; padding-bottom: 2.5pt\">Balance of common stock owed at December 31, 2023</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td id=\"xdx_98A_ecustom--StockBasedCompensation_iE_c20230401__20231231_znt0tA1uab5\" style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\" title=\"Ending balance\"> 6,934,812 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; color: Black; text-align: left\">Term (in years)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 16%; color: Black; text-align: right\"><span id=\"xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20231231_zFRTPp8lOxK7\" title=\"Term (in years)\"> 10 </span></td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 16%; color: Black; text-align: right\"><span id=\"xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zRLjvBhm0pNk\" title=\"Term (in years)\"> 10 </span></td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">Exercise Price</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">$<span id=\"xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zT04rqtFfmDi\" title=\"Exercise Price\"> 0.08 </span>-$<span id=\"xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_z1DVqhNyHJq9\" title=\"Exercise Price\"> 0.09 </span></span></td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">$<span id=\"xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20230331__srt--RangeAxis__srt--MinimumMember_zqlkzyI5c9hf\" title=\"Exercise Price\"> 0.03 </span>-$<span id=\"xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20230331__srt--RangeAxis__srt--MaximumMember_zDs5aiZVRBMj\" title=\"Exercise Price\"> 0.04 </span></span></td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Dividend Yield</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230401__20231231_z8vVzOjujuz9\" title=\"Dividend Yield\"><span style=\"-sec-ix-hidden: xdx2ixbrl1551\">\u2014</span></span></td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220401__20230331_zZKIsNIDxSVk\" title=\"Dividend Yield\"><span style=\"-sec-ix-hidden: xdx2ixbrl1553\">\u2014</span></span></td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left\">Expected Volatility</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><span id=\"xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230401__20231231_zMN6VPzOSjoh\" title=\"Expected Volatility Minimum\"> 80 </span>%-<span id=\"xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230401__20231231_zyJ6xHPahxld\" title=\"Expected Volatility Maximum\"> 81 </span></span></td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><span id=\"xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20220401__20230331_zJfKdkx9zeji\" title=\"Expected Volatility Minimum\"> 79 </span>%-<span id=\"xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20220401__20230331_za8SzvwINcl4\" title=\"Expected Volatility Maximum\"> 80 </span></span></td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Risk Free Rate</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><span id=\"xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230401__20231231_zMgrqqIb2bfg\" title=\"Risk Free Rate Minimum\"> 4.27 </span>%-<span id=\"xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230401__20231231_ztmAdbhxXwC\" title=\"Risk Free Rate Maximum\"> 4.69 </span></span></td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><span id=\"xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220401__20230331_zF9v15QHRwQ7\" title=\"Risk Free Rate Minimum\"> 2.99 </span>%-<span id=\"xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220401__20230331_zCcvXDm7842h\" title=\"Risk Free Rate Maximum\"> 4.01 </span></span></td><td style=\"color: Black; text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"color: Black; font-weight: bold; text-align: center\">Shares</td><td style=\"color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">\u00a0</p> <p style=\"margin-top: 0; margin-bottom: 0\">Weighted</p> <p style=\"margin-top: 0; margin-bottom: 0\"></p></td><td style=\"color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Weighted Average</p> <p style=\"margin-top: 0; margin-bottom: 0\">Remaining Contractual</p></td><td style=\"color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold\">\u00a0</td> <td colspan=\"2\" style=\"color: Black; font-weight: bold; text-align: center\">Aggregate </td><td style=\"color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Underlying Options</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Average</p> <p style=\"margin-top: 0; margin-bottom: 0\">Exercise Price</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Term (in years)</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Intrinsic</p> <p style=\"margin-top: 0; margin-bottom: 0\">Value</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 40%; color: Black; padding-bottom: 1.5pt\">Outstanding at March 31, 2023</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20231231_z7XDnnq6hQx6\" style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\" title=\"Shares Underlying Options, Outstanding, Beginning Balance\"> 15,370,000 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20231231_zlCb4UDxTuM6\" style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\" title=\"Weighted Average Exercise Price, Outstanding, Beginning Balance\"> 0.07 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\"><span id=\"xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331_zDqzlEc1qJJf\" title=\"Weighted Average Remaining Contractual Term (in years), Outstanding\"> 7.4 </span></td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230401__20231231_ztw7DuyC9fFe\" style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\" title=\"Aggregate Intrinsic Value, Outstanding, Beginning Balance\"><span style=\"-sec-ix-hidden: xdx2ixbrl1579\">\u2014</span></td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">Granted</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20231231_zyyu0vzvYFQe\" style=\"color: Black; text-align: right\" title=\"Shares Underlying Options, Granted\"> 4,100,000 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td id=\"xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20231231_zJl4iqHwqxF\" style=\"color: Black; text-align: right\" title=\"Weighted Average Exercise Price, Granted\"> 0.09 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"><span id=\"xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted_dtY_c20230401__20231231_zRMOZG5G4hL5\" title=\"Weighted Average Remaining Contractual Term (in years), Granted\"> 10.0 </span></td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 1.5pt\">Expired and Forfeited</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230401__20231231_zmqP8j9sV6Ij\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Shares Underlying Options, Expired, and Forfeited\">( 3,840,000 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20231231_zeMveNJIEV3k\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Weighted Average Exercise Price, Expired and Forfeited\"> 0.07 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\"><span id=\"xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermExpiredAndForfeited_dtY_c20230401__20231231_z2zy0ek4ANge\" title=\"Weighted Average Remaining Contractual Term (in years), Expired and Forfeited\"> 1.8 </span></td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">\u2014</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; padding-bottom: 1.5pt\">Outstanding at December 31, 2023</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20231231_zGf4ycUMOyv4\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Shares Underlying Options, Outstanding, Ending Balance\"> 15,630,000 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td id=\"xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20231231_zV0Vt58AGaf7\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Weighted Average Exercise Price, Outstanding, Ending Balance\"> 0.05 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\"><span id=\"xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20231231_zIXravG1Jdte\" title=\"Weighted Average Remaining Contractual Term (in years), Outstanding\"> 9.0 </span></td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td id=\"xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230401__20231231_zAKLPewRhRWf\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Aggregate Intrinsic Value, Outstanding, Ending Balance\"> 1,429,822 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; padding-bottom: 1.5pt\">Exercisable at December 31, 2023</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230401__20231231_zuhMIONzmurh\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Shares Underlying Options, Exercisable\"> 343,334 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td id=\"xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230401__20231231_zVsTDpRzAOGh\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Weighted Average Exercise Price, Exercisable\"> 0.19 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\"><span id=\"xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230401__20231231_zKcufK5lIAE\" title=\"Weighted Average Remaining Contractual Term (in years), Exercisable\"> 4.6 </span></td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0d_c20230401__20231231_zC10g50kJvb7\" style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\" title=\"Aggregate Intrinsic Value, Outstanding, Exerciseable\"> 6,850 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20231001__20231231_zTlltkLtQAza\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_498_20221001__20221231_zhugBVqHv0Ua\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_494_20230401__20231231_zZWe1s7PYrX9\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_499_20220401__20221231_zWfLt5fQAmGk\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">For the Three Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; font-weight: bold; font-style: italic; text-align: left\">Operating Income by Segment</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementBusinessSegmentsAxis__custom--AbbreviatedNewDrugApplicationsMember_zXshGcS5Amf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 40%; color: Black; padding-bottom: 1.5pt\">ANDA</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\"> 5,637,283 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\"> 3,828,493 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\"> 13,073,023 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; width: 11%; color: Black; text-align: right\"> 7,947,118 </td><td style=\"width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementBusinessSegmentsAxis__custom--BusinessSegmentMember_za6Xk9oO96fe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 2.5pt\">Operating income by Segment</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 5,637,283 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 3,828,493 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 13,073,023 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 7,947,118 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_499_20231001__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zwsoEXMwrI84\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20221001__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zvr9OuunxMB8\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49D_20230401__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSXfZekaNIwf\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20220401__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4oQa862Bi77\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">For the Three Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--OperatingIncomeLoss_maILFCOzi2J_zRbK0kRSnzpe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 40%; color: Black; text-align: left\">Operating income by segment</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\"> 5,637,283 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\"> 3,828,493 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\"> 13,073,023 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\"> 7,947,118 </td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_ecustom--CorporateUnallocatedCosts_iN_pp0p0_di_msILFCOzi2J_zTfRA3RvB4K1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Corporate unallocated costs</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 1,711,275 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 378,867 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 4,906,187 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 1,465,792 </td><td style=\"color: Black; text-align: left\">)</td></tr> <tr id=\"xdx_404_eus-gaap--InvestmentIncomeInterest_pp0p0_maILFCOzi2J_zpwBXyly29pk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Interest income</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 5,249 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 15 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 16,085 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 187 </td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--InterestAndDebtExpense_iN_pp0p0_di_msILFCOzi2J_zyGV4VYTDgY\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Interest expense and amortization of debt issuance costs</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 121,628 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 322,681 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 371,478 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 782,221 </td><td style=\"color: Black; text-align: left\">)</td></tr> <tr id=\"xdx_40C_eus-gaap--DepreciationAndAmortization_iN_pp0p0_di_msILFCOzi2J_zU181NaHzt51\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Depreciation and amortization expense</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 343,537 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 317,685 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 999,059 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 933,531 </td><td style=\"color: Black; text-align: left\">)</td></tr> <tr id=\"xdx_408_ecustom--NoncashExpense_iN_pp0p0_di_msILFCOzi2J_zDuaaRhC34nj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Significant non-cash items</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 1,711,977 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 172,841 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 1,654,200 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 484,894 </td><td style=\"color: Black; text-align: left\">)</td></tr> <tr id=\"xdx_40C_eus-gaap--GainLossOnSaleOfDerivatives_pp0p0_maILFCOzi2J_zBrenLRPTVEi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Change in fair value of derivative instruments</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 2,417,772 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 372,894 </td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">( 5,075,489 </td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\"> 561,070 </td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_ecustom--ChangeInValueOfNoncashLiabilities_pp0p0_maILFCOzi2J_zckvInuMPcea\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt\">Change in fair value of stock-based liabilities</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">( 2,854,556 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1723\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">( 4,921,376 </td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl1725\">\u2014</span></td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzi2J_zv7FI7NguWp8\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 0pt; color: Black; text-align: left; padding-bottom: 2.5pt\">Income(Loss) before income taxes</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">( 94,259 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 3,009,328 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">( 1,530,281 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\"> 4,841,937 </td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Product</b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Branded</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Product</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Equivalent</b></span></p></td> <td style=\"font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Therapeutic</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Category</b></span></p></td> <td style=\"font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Launch</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Date</b></span></p></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Phentermine HCl 37.5mg tablets</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Adipex-P\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Bariatric</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">April 2011</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Phendimetrazine Tartrate 35mg tablets</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Bontril\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Bariatric</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">November 2012</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Phentermine HCl 15mg and 30mg capsules</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Adipex-P\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Bariatric</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">April 2013</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Naltrexone HCl 50mg tablets</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Revia\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Addiction Treatment</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">September 2013</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Isradipine 2.5mg and 5mg capsules</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">N/A</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Cardiovascular</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">January 2015</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Surmontil\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Antidepressant</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">May 2017</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Adderall\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Central Nervous System Stimulant</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">April 2019</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Dantrolene Sodium Capsules 25mg, 50mg and 100mg</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Dantrium\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Muscle Relaxant</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">June 2019</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Adderall XR\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Central Nervous System Stimulant</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">March 2020</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Loxapine\u00ae</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Antipsychotic</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">May 2021</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Three Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 38%; color: Black; text-align: left\">Manufacturing fees</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">14,791,110</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">7,798,159</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">6,992,951</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">90</td><td style=\"width: 3%; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left; padding-bottom: 1.5pt\">Licensing fees</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">747,690</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">1,451,907</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">(704,217</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">(49</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Total revenue</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">15,538,800</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">9,250,066</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">6,288,734</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">68</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; padding-bottom: 1.5pt\">Cost of manufacturing</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">8,497,727</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">4,330,841</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">4,166,886</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">96</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 2.5pt\">Gross profit</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">7,041,073</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">4,919,225</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">2,121,848</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">43</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gross profit - percentage</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">45</td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">53</td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Three Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Operating expenses:</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 40%; color: Black; text-align: left\">Research and development</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">1,403,790</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">1,443,361</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">(39,571</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">(3</td><td style=\"width: 1%; color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">General and administrative</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,711,275</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,186,049</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">525,226</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">44</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Non-cash compensation</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">49,815</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">13,030</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">36,785</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">282</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt\">Depreciation and amortization</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">343,537</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">317,685</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">25,852</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">8</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; color: Black; text-align: left; padding-bottom: 2.5pt\">Total operating expenses</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">3,508,417</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">2,960,125</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">548,292</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">19</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Three Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Other income (expense):</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 38%; color: Black; text-align: left\">Change in fair value of derivative financial instruments - warrants</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">(2,417,772</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">372,894</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">(2,790,666</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">(748</td><td style=\"width: 3%; color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Change in fair value of stock-based liabilities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(2,854,556</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(2,854,556</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Interest expense and amortization of debt issuance costs</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(121,628</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(322,681</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">201,053</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(62</td><td style=\"color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gain from settlement agreements</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,761,792</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,761,792</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gain on sale of ANDA</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,000,000</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(1,000,000</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(100</td><td style=\"color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt\">Interest income</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">5,249</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">15</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">5,234</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">34,893</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; color: Black; text-align: left; padding-bottom: 2.5pt\">Other (expense) income, net</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(3,626,915</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">1,050,228</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(4,677,143</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(445</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Nine Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 40%; color: Black; text-align: left\">Manufacturing fees</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">36,208,217</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">21,312,663</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">14,895,554</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">70</td><td style=\"width: 1%; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left; padding-bottom: 1.5pt\">Licensing fees</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">2,467,844</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">4,200,888</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">(1,733,044</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">(41</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Total revenue</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">38,676,061</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">25,513,551</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">13,162,510</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">52</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; padding-bottom: 1.5pt\">Cost of manufacturing</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">20,437,354</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">12,360,935</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">8,076,419</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">65</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left; padding-bottom: 2.5pt\">Gross profit</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">18,238,707</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">13,152,616</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">5,086,091</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">39</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gross profit - percentage</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">47</td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">52</td><td style=\"color: Black; text-align: left\">%</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Nine Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Operating expenses:</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 40%; color: Black; text-align: left\">Research and development</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">5,165,684</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">3,775,107</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">1,390,577</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">37</td><td style=\"width: 1%; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">General and administrative</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">4,906,187</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">4,356,752</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">549,435</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">13</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Non-cash compensation</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">107,592</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">24,325</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">83,267</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">342</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt\">Depreciation and amortization</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">999,059</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">933,531</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">65,528</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">7</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; color: Black; text-align: left; padding-bottom: 2.5pt\">Total operating expenses</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">11,178,522</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">9,089,715</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">2,088,807</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">23</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">For the Nine Months Ended</p> <p style=\"margin-top: 0; margin-bottom: 0\">December 31,</p></td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Dollars</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Percentage</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Other income (expense):</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u00a0</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; width: 38%; color: Black; text-align: left\">Change in fair value of derivative financial instruments - warrants</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">(5,075,489</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">561,070</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 11%; color: Black; text-align: right\">(5,636,559</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 11%; color: Black; text-align: right\">(1,005</td><td style=\"width: 3%; color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Change in fair value of stock-based liabilities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(4,921,376</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(4,921,376</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">100</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Interest expense and amortization of debt issuance costs</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(371,478</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(782,221</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">410,743</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(53</td><td style=\"color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gain from settlement agreements</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,761,792</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,761,792</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 10pt; color: Black; text-align: left\">Gain on sale of ANDA</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">\u2014</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">1,000,000</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(1,000,000</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; text-align: right\">(100</td><td style=\"color: Black; text-align: left\">)%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt\">Interest income</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">16,085</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">187</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">15,898</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; color: Black; text-align: right\">8,502</td><td style=\"padding-bottom: 1.5pt; color: Black; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 20pt; color: Black; text-align: left; padding-bottom: 2.5pt\">Other (expense) income, net</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(8,590,466</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">779,036</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">\u00a0</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(9,369,502</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)</td><td style=\"color: Black; padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; color: Black; text-align: right\">(1,203</td><td style=\"padding-bottom: 2.5pt; color: Black; text-align: left\">)%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">March 31, 2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">Change</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 40%; color: Black; text-align: left\">Current assets</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 16%; color: Black; text-align: right\">37,156,502</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 16%; color: Black; text-align: right\">21,510,297</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 16%; color: Black; text-align: right\">15,646,205</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left\">Current liabilities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">19,158,799</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">7,833,637</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">11,325,162</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Working capital</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">17,997,703</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">13,676,660</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">4,321,043</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">For the Nine Months Ended December 31,</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"color: Black\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td><td style=\"color: Black; font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; color: Black; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; color: Black; text-align: left\">Net cash (used in) provided by operating activities</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 16%; color: Black; text-align: right\">(5,341,537</td><td style=\"width: 1%; color: Black; text-align: left\">)</td><td style=\"width: 2%; color: Black\">\u00a0</td> <td style=\"width: 1%; color: Black; text-align: left\">$</td><td style=\"width: 16%; color: Black; text-align: right\">370,021</td><td style=\"width: 1%; color: Black; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"color: Black; text-align: left\">Net cash used in investing activities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">(406,007</td><td style=\"color: Black; text-align: left\">)</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">(5,200,407</td><td style=\"color: Black; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"color: Black; text-align: left\">Net cash provided by financing activities</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">3,747,073</td><td style=\"color: Black; text-align: left\">\u00a0</td><td style=\"color: Black\">\u00a0</td> <td style=\"color: Black; text-align: left\">$</td><td style=\"color: Black; text-align: right\">14,204,231</td><td style=\"color: Black; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"border-bottom: black 2.25pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Exhibit No.</b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"border-bottom: black 2.25pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>Description</b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">31.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><a href=\"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006661/ex31-1.htm\">Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">31.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><a href=\"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006661/ex31-2.htm\">Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">32.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><a href=\"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006661/ex32-1.htm\">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">32.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><a href=\"https://www.sec.gov/Archives/edgar/data/1053369/000149315224006661/ex32-2.htm\">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.INS</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Instance Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.SCH</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Taxonomy Schema Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.CAL</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.DEF</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.LAB</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">101.PRE</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">104</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td colspan=\"2\" style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><b>ELITE PHARMACEUTICALS, INC.</b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 50%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 3%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 47%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">February 14, 2024</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">By:</span></td> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><i>/s/ Nasrat Hakim</i></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Nasrat Hakim</span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Chief Executive Officer, President and Chairman of the Board of Directors</span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">(Principal Executive Officer)</span></p></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">February 14, 2024</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">By:</span></td> <td style=\"border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\"><i>/s/ Carter Ward</i></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Carter Ward</span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">Chief Financial Officer</span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black\">(Principal Accounting and Financial Officer)</span></p></td></tr> </table>"
    ]
}